Category: Health

A groundbreaking legal battle against major tech companies continues Thursday in Los Angeles, where a California woman is scheduled to give testimony about how childhood exposure to social media platforms damaged her mental well-being.

The plaintiff, identified in legal documents as Kaley G.M., started using YouTube when she was just 6 years old and began accessing Instagram at age 9. She alleges these early experiences with social media led to serious mental health struggles, including depression and body dysmorphia.

According to her legal team, both Meta Platforms and Google deliberately designed their services to create dependency among young users while being fully aware that social media exposure could cause psychological harm to children.

Her scheduled court appearance follows testimony from her previous psychotherapist, who told the court Wednesday that teenage social media use was a “contributing factor” in the woman’s psychological difficulties.

This legal challenge reflects a growing worldwide movement to hold social media companies accountable for potential damage to young people’s mental health. Australia recently implemented a complete ban on social media access for anyone under 16, while several other nations are exploring similar protective measures.

Both YouTube and Meta have rejected these accusations, stating that the evidence presented does not validate the plaintiff’s assertions about their platforms causing harm.

The plaintiff’s legal representatives brought in the therapist to establish groundwork for the current trial phase, which examines whether and how Kaley’s childhood interaction with these platforms impacted her psychological state.

Earlier portions of the trial concentrated on examining what these companies understood about social media’s effects on children and their marketing approaches targeting younger demographics. Meta’s CEO Mark Zuckerberg provided testimony indicating his company considered but ultimately decided against launching products specifically for children.

For a successful outcome, Kaley’s attorneys must demonstrate that the companies’ platform design or operational methods played a significant role in either causing or intensifying her mental health problems.

Country music legend Dolly Parton is expanding her philanthropic reach by supporting children’s healthcare in Tennessee. The East Tennessee Children’s Hospital revealed Thursday it has been renamed Dolly Parton Children’s Hospital following a major donation from the Grammy-winning artist.

In a video message, Parton expressed her commitment to helping young patients and their families. “Ever since I’ve been in a position to do my part, to help others, I have tried to do just that. Especially when children and families need it most,” Parton said in a video announcement. “I’ve always believed that every child deserves a fair chance to grow up healthy, hopeful and surrounded with love.”

The country star’s charitable work extends far beyond this latest contribution. Through her Imagination Library program, Parton distributes 3 million complimentary books monthly to children nationwide. She also contributed $1 million toward Vanderbilt University Medical Center’s research efforts that supported development of the Moderna COVID-19 vaccine. Her foundation additionally funds college scholarships and disaster relief efforts.

While hospital officials did not disclose the donation amount, President and CEO Matt Schaefer emphasized that Parton’s contribution will guarantee “every child who walks through our doors receives the treatment they deserve.”

Adam Cook, who serves as the independent nonprofit facility’s chief development and public affairs officer, assured the community that patient care standards will remain unchanged. The donation “encourages us to continue to support our mission,” Cook noted.

“This is a generational collaboration that will transform pediatric care in this region,” Cook said in a statement to the Associated Press. “It will positively impact patients and families for decades to come.”

The financial backing arrives during a challenging period when rural medical facility closures have reduced healthcare access for millions of Americans.

Since opening its doors in 1937, the medical center has maintained a policy welcoming all children regardless of background, faith, or financial circumstances. The primary facility in Knoxville serves as the hub for more than 20 locations throughout eastern Tennessee.

Parton expressed gratitude for the opportunity to support the hospital’s medical staff and encouraged community involvement. “I can’t do it all myself,” she said in the video.

A federal health advisory panel will examine COVID-19 vaccine side effects and persistent coronavirus symptoms during an upcoming meeting next month, according to a government announcement.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is scheduled to discuss and potentially vote on guidance related to COVID vaccine injuries and long COVID symptoms at their March 18-19 gathering, based on documentation filed in the Federal Register.

The committee’s guidance traditionally influences how health insurers make coverage decisions, shapes state requirements for school vaccinations, and helps doctors counsel their patients and families. Last year, the entire 17-member panel was dismissed and replaced by Health and Human Services Secretary Robert F. Kennedy Jr., who has expressed skepticism about vaccines.

Social media wellness gurus are promoting a technique they say can transform high-calorie foods like rice, pasta, and potatoes into diet-friendly alternatives simply by refrigerating them after cooking.

While their claims aren’t entirely accurate, researchers have found some legitimate science behind this cooling method that could benefit those trying to manage their weight.

For years, health and nutrition influencers have been advocating for a scientific process known as retrogradation. They encourage followers to cook starchy foods, refrigerate them, and then warm them up again, promising this technique will reduce the caloric content.

The process of retrogradation does exist, though the reality is more nuanced than social media suggests.

The bulk of carbohydrates and calories in these foods comes from starch, which exists in two forms: amylose, which resists digestion, and amylopectin, which breaks down easily. Amylopectin gets processed rapidly and causes blood sugar to surge, while amylose digests slowly and keeps blood sugar more steady.

Raw starchy foods like uncooked potatoes contain primarily the difficult-to-digest variety (known as resistant starch), but the cooking process transforms it into the easily processed type. This transformation explains why people with diabetes must carefully monitor their intake of cooked starches.

The cooling process that excites influencers works like this: refrigerating cooked starches initiates retrogradation, which changes the easily digested starch back into the resistant form, making it harder for the body to process even after reheating.

So what does this mean for calorie counts and blood sugar management? Here’s what research reveals:

Scientific investigations into retrogradation’s dietary effects have typically been limited in scope and have concentrated on how resistant starches affect blood glucose, especially in diabetic patients.

Several research studies conducted since 2015 have demonstrated that participants who consumed rice that had been cooked and subsequently chilled experienced notably lower blood glucose responses compared to those who ate freshly prepared rice. These results have gained broad scientific acceptance.

However, fewer studies have examined whether retrogradation actually decreases the available calories in these foods.

Dr. David Ludwig, an endocrinologist and researcher at Boston Children’s Hospital, offers a measured perspective. “It doesn’t appreciably change the calorie content of that food,” he explained. “(But) it may well affect your hormones and metabolism in a way that makes controlling calories a lot easier.”

While retrogradation’s impact on calories isn’t as immediate or significant as some claim, Ludwig believes it still holds value as part of a healthier eating approach.

Consuming foods rich in resistant starch prevents the typical blood sugar spike that occurs after eating cooked carbohydrates, he noted. This benefit extends beyond diabetic patients.

Research indicates that these sugar spikes stimulate the brain’s reward pathways and create cravings, increasing the likelihood of overeating during snacks and subsequent meals.

Additionally, these blood sugar surges boost insulin production, which not only increases hunger but also shifts the body’s metabolism toward storing more calories as fat, Ludwig explained.

“When the food retrogrades, it digests more slowly,” he said. “It’s going to keep your blood sugar more stable. You’ll have less insulin to drive fat storage and likely have an easier time avoiding overeating.”

While chilling can theoretically reduce some negative effects of a diet heavy in refined starches, Dr. Walter Willett, professor of epidemiology and nutrition at Harvard T.H. Chan School of Public Health, questions its practicality. He says it would need to be done consistently to be effective, and he doubts whether most people can maintain this practice.

The process also isn’t universally applicable. Retrogradation produces better results with certain grain types than others. Food manufacturers often prefer rice varieties that naturally contain less resistant starch because they cook faster. Since this information typically isn’t available to shoppers, consumers can’t easily determine when chilling will make a meaningful difference.

Willett also emphasized that retrogradation only addresses blood sugar concerns.

“Chilling does not restore the losses of fiber, minerals and vitamins that have been removed in the refining process,” he said.

Instead, he recommends a simpler approach: replacing refined grains with minimally processed whole grains prepared using standard cooking methods.

Meta announced Thursday that Instagram will begin sending alerts to parents when their teenage children conduct multiple searches for content related to suicide or self-harm. These notifications will only reach families who have signed up for the platform’s existing parental supervision tools.

The social media giant explained that it currently prevents such harmful content from appearing in teenagers’ search results and instead redirects users to mental health resources and crisis hotlines.

This new safety measure arrives while Meta faces significant legal challenges concerning child protection. Currently, a Los Angeles courtroom is examining allegations that Meta’s social platforms intentionally create addiction and cause harm to young users. Simultaneously, a separate case in New Mexico is investigating whether the company adequately shields children from sexual predators on its services. Numerous families, school systems, and government agencies have filed lawsuits against Meta and competing social media companies, alleging these platforms are purposely designed to create dependency while failing to protect young users from harmful content that may contribute to depression, eating disorders, and suicidal thoughts.

Company leadership, including CEO Mark Zuckerberg, has rejected claims that their platforms cause addiction. While testifying under oath in the Los Angeles proceedings, Zuckerberg maintained his position that current scientific research has not established a causal link between social media use and mental health problems.

Parents will receive these safety alerts through multiple channels including email, text messages, or WhatsApp notifications, based on their available contact details, plus direct notifications within their own Instagram accounts.

“Our goal is to empower parents to step in if their teen’s searches suggest they may need support. We also want to avoid sending these notifications unnecessarily, which, if done too much, could make the notifications less useful overall,” Meta explained in their official announcement.

The company also revealed plans for additional parental notifications regarding teenagers’ conversations with artificial intelligence systems. “These will notify parents if a teen attempts to engage in certain types of conversations related to suicide or self-harm with our AI,” Meta stated. “This is important work and we’ll have more to share in the coming months.”

Pharmaceutical company Eli Lilly shared updated findings Thursday from a clinical comparison study involving their experimental weight-loss medication orforglipron and competitor Novo Nordisk’s oral diabetes drug in diabetic patients, providing more comprehensive information about adverse reactions.

The study revealed that approximately 58% of participants taking the higher 36-milligram dosage of Lilly’s experimental medication experienced mild-to-moderate adverse reactions, including nausea, diarrhea and vomiting. In contrast, 45% of patients receiving the 14-milligram dose of oral semaglutide reported similar issues.

Novo Nordisk markets oral semaglutide as Rybelsus for type 2 diabetes patients to manage blood sugar levels. The trial showed that roughly 10% of participants receiving the 36-milligram orforglipron dosage stopped their treatment due to adverse effects, while only 5% of those taking 14-milligram Rybelsus discontinued therapy for the same reason.

Participants taking orforglipron also experienced an average increase in heart rate during the study period.

Earlier results released in September demonstrated that the 36-milligram orforglipron dosage reduced average blood glucose levels by 2.2%, outperforming the 1.4% reduction seen with 14-milligram Rybelsus.

Weight loss results showed participants on 36-milligram orforglipron shed an average of 8.9 kilograms (19.7 pounds), representing 9.2% of their body weight. Those taking 14-milligram Rybelsus lost an average of 5 kilograms (11 pounds), or 5.3% of their weight.

“We think that the totality of the profile here is a trade-off that patients will be very happy to make because they are getting better glycemic control and better weight loss as well as no restriction on dosing with food and water,” said Kenneth Custer, president of Lilly Cardiometabolic Health.

Both Lilly’s orforglipron and Rybelsus work by mimicking the appetite-suppressing GLP-1 hormone, the same target as Lilly’s successful injectable medication tirzepatide, which is marketed as Mounjaro and Zepbound.

National Public Radio host A Martinez recently sat down with Jerome Adams, the former United States Surgeon General, to discuss the upcoming confirmation process for the person anticipated to become the country’s next chief medical officer.

The conversation focused on the hearing process that will determine whether the nominee will be approved for the nation’s top health position.

European regulators announced Wednesday they are implementing strict new safety measures for importing a key ingredient used in baby formula from China, following a contamination crisis that made dozens of infants sick across the continent.

The European Commission said it will now require special safety certificates for all shipments of arachidonic acid (ARA) oil coming from Chinese suppliers after batches tainted with cereulide toxin entered the baby formula supply chain, causing nausea and vomiting in infants.

Major baby formula manufacturers including Nestle and Danone were forced to pull products from store shelves in widespread recalls that resulted in millions of dollars in financial losses.

According to the commission’s announcement Wednesday, the Chinese-sourced arachidonic acid oil “was likely to constitute a serious risk for human health.”

“Consignments should be accompanied by an official certificate stating that all the results of sampling and analyses show the absence of cereulide toxin,” the commission said.

“To ensure food safety and to avoid the entry into the union of unsafe arachidonic acid oil originating in China, this regulation should enter into force as a matter of urgency.”

Formula manufacturers have stopped purchasing supplies from Cabio Biotech, the Chinese company identified as the source of the tainted ingredient. The company did not respond to requests for comment.

When questioned about Cabio Biotech’s involvement in the recall crisis earlier this month, Chinese foreign ministry spokesperson Lin Jian said: “I would like to point out that the Chinese government takes food safety very seriously and will continue to take strong measures to safeguard the legitimate rights and interests of consumers.”

California wildlife officials have shut down popular elephant seal viewing tours after confirming that seven seal pups have contracted avian flu at Año Nuevo State Park. Additional animals are displaying symptoms of the illness, researchers announced Wednesday.

Scientists from UC Santa Cruz and UC Davis confirmed this marks the first documented case of the bird flu virus affecting marine mammals in California waters.

The global avian flu pandemic that started in 2020 has killed millions of domestic birds and infected wildlife across the globe. Marine mammals like seals and sea lions have proven especially susceptible to the disease. Recent outbreaks have claimed thousands of sea lions in Chile and Peru, thousands of elephant seals in Argentina, and hundreds of seals along New England’s coast.

While health officials consider the virus low-risk for humans, they’re urging the public to stay away from the seals and keep pets at a safe distance.

Each winter, thousands of massive elephant seals migrate to Año Nuevo State Park, located roughly 90 minutes south of San Francisco, for their breeding season activities including fighting, mating and birthing. This natural phenomenon attracts countless tourists and nature enthusiasts who come to observe Earth’s largest seal species, either from designated public areas or through guided docent-led excursions into the breeding colonies.

The park’s viewing areas are now closed and all tours have been suspended “out of an abundance of caution,” according to Jordan Burgess, deputy district superintendent for California’s Department of Parks and Recreation. Officials believe this action will help prevent potential disease transmission that could occur from human foot traffic through elephant seal habitats, she explained.

“We’re definitely not panicking about human exposure at this point,” Burgess stated, emphasizing that the priority is protecting both seal populations and public health.

Christine Johnson, who heads UC Davis’ Institute for Pandemic Insights at the Weill School of Veterinary Medicine, said researchers detected the outbreak rapidly due to heightened surveillance efforts in recent years. After observing sick and deceased animals on February 19th and 20th, scientists gathered samples for analysis at the California Animal Health and Food Safety Laboratory System. Laboratory results confirmed the presence of HPAI H5N1 virus in the specimens.

Approximately 30 additional animal samples are awaiting test results, Johnson noted.

University scientists are collaborating with state and federal wildlife agencies along with The West Coast Marine Mammal Stranding Network to continue monitoring the affected animals.

A tragic incident in Rhode Island serves as a deadly reminder of winter weather dangers after a college football player lost his life to carbon monoxide poisoning while trying to charge his phone during a power outage.

Joseph Boutros, a 21-year-old student at Salve Regina University, was discovered unresponsive in his vehicle Monday outside a campus building in Newport, Rhode Island. Emergency responders determined the young man died accidentally from carbon monoxide exposure after snow from a major winter storm blocked his car’s exhaust system.

The massive storm had left hundreds of thousands without electricity throughout the Northeast region. Newport Police Captain Joseph Carroll explained that Boutros had informed another student he planned to use his vehicle to charge his phone since the area had lost power. The university’s football program expressed being “heartbroken” over Boutros’ passing in a social media announcement.

Rhode Island residents continued dealing with storm aftermath Wednesday, with many facing a third consecutive day trapped at home due to unplowed neighborhood streets.

While winter storms bring obvious dangers like icy conditions and freezing temperatures, one of the deadliest threats from heavy snowfall remains invisible to human senses.

Understanding carbon monoxide dangers becomes crucial during power failures and frigid weather conditions.

Winter months and periods following significant snowfall create elevated carbon monoxide poisoning risks, according to Centers for Disease Control data. Cold temperatures lead people to rely more heavily on heating equipment and furnaces that produce this deadly gas.

Various equipment failures can block adequate ventilation systems, with accumulated snow frequently obstructing exhaust outlets and air vents.

Medical professionals call carbon monoxide the “silent killer” since people cannot smell, see, or taste this dangerous substance. Extended contact with carbon monoxide prevents blood from delivering oxygen to vital body organs.

Initial symptoms include severe headaches, confusion, and fatigue, which progress to loss of consciousness, seizures, and ultimately death.

Dangerous carbon monoxide accumulation occurs when individuals operate heating equipment without adequate airflow or ventilation systems — including running vehicles in enclosed garages, moving outdoor grills indoors, or using gas cooking appliances for warmth. Tragic situations similar to Monday’s fatal incident often involve people waiting in vehicles for extended periods without realizing blocked exhaust systems.

A significant historical example occurred during 1978, when a severe snowstorm dumped two feet of snow across New England within approximately 30 hours. The rapid snowfall stranded about 3,000 automobiles and 500 commercial trucks along an eight-mile stretch of Massachusetts highway, according to New England Historical Society records.

During that storm, 14 individuals died from carbon monoxide exposure while trapped in their snow-covered vehicles.

Vehicle-related incidents represent just one danger source. A devastating 2022 storm claimed more than three dozen lives, including at least one person who died when snow covered heating system vents and sent carbon monoxide into their New York residence.

Jake Fisher, Consumer Reports’ senior director of automotive testing, notes that sitting in running vehicles typically poses minimal risk under normal circumstances. However, drivers should watch for warning indicators and schedule annual vehicle inspections. Automobiles become more susceptible to exhaust system leaks following accidents and require professional evaluation before returning to service.

“Engines emit a lot of very dangerous chemicals and gases,” Fisher said. “If your car is not running right and you hear it sounding funny, you really do need to get it checked out.”

Pharmaceutical company Gilead Sciences announced Wednesday that their investigational HIV medication in single-tablet form demonstrated strong patient tolerance with minimal dropout rates during clinical testing, potentially offering HIV patients a new treatment option once their viral levels are controlled.

The company shared comprehensive findings from an advanced clinical study at a Denver medical conference Wednesday, as they prepare to seek regulatory approval for the experimental drug combination.

Study data revealed that patients stopped taking the medication due to side effects at rates of just 1.6% and 0.5% across the two study groups, figures researchers considered notably low.

After 48 weeks of treatment in the same study, only 0.8% of participants taking the new single-pill combination showed detectable virus levels in their bloodstream, while 1.1% of those continuing their previous multiple-pill treatments had detectable viral loads.

Researchers tested the medication in HIV patients who already had suppressed viral levels, including individuals transitioning from complicated multiple-pill treatment plans or from currently recommended single-tablet therapies.

Study participants also indicated greater satisfaction with their treatment after making the switch to the investigational medication, based on findings published in The Lancet medical journal.

The pharmaceutical company stated they intend to provide data from both clinical trials to regulatory agencies for review. No regulatory body has yet granted approval for this drug combination.

Health authorities in South Carolina are seeing hopeful signs that the country’s most significant measles outbreak in over three decades may be beginning to subside, with infections declining for two consecutive weeks.

During a Wednesday briefing, state epidemiologist Dr. Linda Bell credited the dedicated efforts of public health workers for the positive trend. “The hard work and long hours that frontline, often entry-level epidemiologists, have put into this response are largely responsible for this downward trend that is actually occurring a bit earlier than previously projected,” Bell stated, while cautioning that the outbreak “is not by any means over.”

South Carolina has enlisted assistance from infectious disease specialists through the nonprofit CDC Foundation to help manage the crisis, which has become the most extensive measles outbreak nationwide since 1992. As of Tuesday, health officials have documented 979 confirmed cases.

The disease surge started in October and has primarily affected communities in the state’s northwestern counties, particularly around Greenville and Spartanburg areas.

Federal health officials announced Wednesday that they have cleared a new liquid medication designed to treat a rare hormone disorder in children, providing families with a more convenient treatment option.

The Food and Drug Administration authorized Eton Pharmaceuticals’ medication called Desmoda, an oral liquid version of desmopressin specifically formulated to treat central diabetes insipidus, also known as arginine vasopressin deficiency. This uncommon condition occurs when the body cannot produce enough of the hormone responsible for controlling water balance, leading to extreme thirst and frequent urination.

Medical experts say the new approval tackles a significant treatment challenge, as physicians must precisely calibrate medication doses to maintain proper fluid levels and prevent harmful changes in sodium concentrations, particularly in young patients.

Company officials project that Desmoda could bring in between $30 million and $50 million in yearly revenue at its peak performance.

Vanderbilt University Medical Center has discontinued its gender transition surgical services, becoming another healthcare facility to halt these procedures amid concerns over potential federal funding cuts under the Trump administration. The Nashville-based medical center’s decision comes as President Trump has pledged to prevent taxpayer money from funding medical treatments aimed at helping individuals transition to live as a different gender.

Vanderbilt’s situation draws particular attention due to a 2022 incident where one of the medical center’s administrators was recorded on video justifying gender transition surgeries by stating that “these surgeries make a lot of money.” This recording brought significant scrutiny to the institution’s motivations for offering such services.

The medical center joins a growing list of hospitals across the country that have ceased providing these surgical procedures as healthcare institutions navigate the changing federal policy landscape regarding gender transition treatments.

An Indian pharmaceutical company is preparing to introduce a more affordable alternative to popular diabetes and weight-loss medications next month, according to industry sources and documents obtained by Reuters.

Dr Reddy’s Laboratories, headquartered in Hyderabad, is expected to roll out its generic semaglutide injection in India during March, marketing it under the brand name Obeda. The medication contains the same active ingredient found in Novo Nordisk’s widely-used diabetes treatment Ozempic and weight-loss medication Wegovy.

Government records show that the Indian drugmaker has submitted trademark applications for both the Obeda brand name and its associated logo.

When contacted for comment, a company representative stated: “As semaglutide is yet to be officially launched, it would not be appropriate to refer to or publish any name as the brand name at this stage.” The pharmaceutical company declined to specify whether their Obeda product will target diabetes treatment or weight management.

The timing coincides with approaching patent expiration dates, as semaglutide’s intellectual property protection in India concludes in March 2026. This has sparked competition among Indian drug manufacturers to develop cost-effective alternatives.

India faces significant health challenges that make such medications particularly relevant. The nation ranks second globally in adult diabetes cases, trailing only China, according to International Diabetes Federation data. Research published in The Lancet projects that India could see more than 440 million people classified as overweight or obese by 2050.

Company leadership has outlined ambitious sales projections for the new product. G.V. Prasad, who serves as Co-Chairman and Managing Director of Dr Reddy’s, revealed plans to distribute approximately 12 million injectable semaglutide pens during the initial year. The pricing strategy aims to undercut existing branded products substantially, potentially offering savings of up to 60%.

The company has secured regulatory permission to produce and distribute a generic equivalent of Ozempic, while still awaiting approval for a Wegovy alternative. Although Ozempic received official approval specifically for diabetes management, medical professionals frequently prescribe it for weight reduction purposes.

The competitive landscape intensified last year when both Novo Nordisk and American competitor Eli Lilly introduced their diabetes and weight-loss treatments to the Indian market. Lilly’s Mounjaro quickly achieved the distinction of becoming India’s highest-grossing medication by monetary value.

Acknowledging the competitive environment ahead, Prasad commented: “Everybody is going to launch, so we’ll have to figure out who will get market share.”

Fancy bottles and compelling marketing messages promising miracle hair transformations often make shoppers question whether they should swap their budget-friendly drugstore shampoo for a luxury product costing five times more.

Hair care specialists and dermatologists confirm that reasonably-priced shampoos and conditioners available at local stores can perform just as effectively as their high-end counterparts that feature attractive social media campaigns and celebrity endorsements. Medical professionals recommend that consumers focus on ingredient lists, understand their specific scalp conditions and hair needs, and consider their complete styling routine — consulting a physician when uncertain about persistent issues.

High-end products may perform effectively and sometimes contain costly active components, dermatologists note. Additional pricing factors include company size and investments in organic components, environmentally-friendly farming practices, and recyclable packaging materials.

Dr. Crystal Aguh, who serves as a dermatologist and heads the Ethnic Skin Program at Johns Hopkins School of Medicine, explained that she typically divides patients into two categories: those with damage-prone hair and those with damage-resistant hair.

The damage-prone category encompasses individuals with highly curled hair, those who apply chemical treatments, and people who regularly use heated styling equipment. She noted that damage-resistant characteristics include naturally oily and straight hair textures.

Individuals with fragile hair should steer clear of shampoos listing sodium lauryl sulfate as a primary component, Aguh explained. This ingredient strips away significant amounts of sebum, the natural protective oil coating that shields hair strands. When sebum is removed, hair may become extremely dry and prone to breakage.

For individuals with curly or chemically-treated hair, Aguh suggests reducing washing frequency to prevent excessive sebum removal. She recommended that people with tightly coiled hair should cleanse only once weekly. Those with wavy, color-treated hair might achieve better results washing every two to three days.

Hair that resists damage and tends toward oiliness with straight texture can handle daily washing routines.

While costly shampoos and conditioners may deliver good results, budget-friendly alternatives can achieve comparable performance, Aguh stated. She emphasizes to her patients that “it’s not the products, it’s the process” that most significantly impacts hair wellness, including washing frequency, coloring treatments, and heat styling habits.

“Instead of spending hundreds of dollars thinking, ‘If I just find the right shampoo, right conditioner, all of my troubles will go away,’ you also have to just look at what your process looks like … because that will often do the trick,” she explained.

She confirmed that combining premium and mass-market products works perfectly fine, and consumers shouldn’t feel pressured to purchase complete product lines from expensive brands.

According to Aguh, certain popular brands maintain lower prices because large corporations manufacture them, allowing for cost savings through mass production. In contrast, expensive brands may operate with smaller teams and limited resources, preventing them from achieving similar cost efficiencies.

For dandruff treatment specifically, Aguh frequently suggests over-the-counter options rather than prescription treatments. However, she stressed that persistent dandruff concerns warrant medical consultation.

Dr. Joe Tung, a dermatologist with the University of Pittsburgh Medical Center, advised people to view shampoo as scalp skincare rather than merely a beauty product.

“Hair itself is biologically inactive once it grows out, but underneath the surface of the skin on the scalp is a full ecosystem with stem cells, immune cells, oil glands, nerve endings,” he explained. “When that ecosystem is balanced, the scalp feels comfortable and hair grows optimally; when it is disrupted, people can experience itching, flaking, excess oil, or hair loss.”

Tung emphasized that consumers should prioritize their scalp’s requirements when selecting shampoo, while conditioner choices should depend on hair texture and existing damage. He noted that dandruff and scalp irritation respond well to shampoos targeting inflammation and bacterial imbalances, while dry or chemically-processed hair benefits from mild cleansers paired with nourishing conditioners.

While expensive hair care products sometimes justify their cost, Tung stressed that a product’s performance depends on active ingredients rather than marketing appeal. “An antifungal ingredient works because of its molecular activity, not because it comes in a luxury bottle or from a prestigious brand,” he stated.

Premium shampoos often feature more sophisticated conditioning compounds and calming ingredients that may enhance comfort during frequent washing, Tung noted. However, some luxury formulations include fragrances or plant extracts that might irritate sensitive skin. He pointed out that straightforward formulas typically work better for people with skin sensitivities.

MOKO Organic Beauty Studio in Philadelphia carries organic shampoos and conditioners priced between $24 and $45. Owner Monique Mason described the salon’s commitment to offering products beneficial for both scalps and environmental health.

Mason identified ingredients as the primary factor affecting price among various considerations. Organic formulations typically exclude inexpensive sulfates, artificial fragrances, and parabens commonly found throughout the personal care market, she explained. Mason also investigates the manufacturing practices of brands she carries to verify their environmental responsibility claims.

“I get to know them, whether they’re family-owned, how they farm, how they source their ingredients,” she said.

In Columbus, Ohio, some young children are getting their reading abilities evaluated before they even step foot in a classroom — it’s happening right in their pediatrician’s office.

As childhood literacy struggles continue nationwide, Nationwide Children’s Hospital has launched a program to evaluate reading skills during routine medical visits for children beginning at age 3. The goal is to identify potential reading difficulties before they become bigger problems and provide parents with tools to support their children at home.

“They are all doing developmental screenings, they’re all talking to parents repeatedly,” explained Sara Bode, who serves as the hospital’s medical director of school-based health. “So this is an opportunity.”

The hospital strategically selected clinic locations based on their closeness to schools where students scored poorly on kindergarten readiness evaluations. Data from the state’s kindergarten readiness assessment shows that over 63% of kindergarten students in Columbus City Schools were not meeting language and literacy benchmarks during the current 2024-2025 academic year.

The literacy crisis extends well beyond Columbus borders. According to the 2024 National Assessment of Educational Progress — commonly referred to as the nation’s report card — only slightly more than 30% of fourth-grade students demonstrate reading proficiency nationwide. This represents a decline of 4 percentage points since 2019, as educational systems continue working to recover from pandemic-related learning setbacks.

While medical facilities don’t traditionally conduct reading evaluations, several major pediatric hospitals, including Boston Children’s Hospital, have begun offering early literacy resources to families, recognizing how crucial reading skills are for child development.

Children who start kindergarten with weaker reading abilities typically find it difficult to improve in subsequent years. Research from The Children’s Reading Foundation shows that nearly three-quarters of kindergarteners who score in the lowest 20% on readiness tests remain in that bottom tier through fifth grade.

Medical professionals have historically concentrated their developmental evaluations on physical milestones like walking and speaking at appropriate ages. However, Bode noted that children might pass standard pediatric screenings while still lacking other essential skills needed for kindergarten success.

To tackle this challenge, the pediatric facility rolled out literacy evaluations at approximately half of its 13 clinic locations, with each site having a dedicated literacy coordinator. Since the program’s 2022 launch, staff have completed over 2,400 assessments. The hospital primarily serves families without insurance or those covered by Medicaid, representing high-needs communities.

The screenings don’t aim to diagnose specific learning disorders such as dyslexia, but instead pinpoint areas where children might benefit from extra help.

Devin Kearns, an early literacy expert at North Carolina State University, believes having resources beyond the school system to catch reading problems early is beneficial, though selecting appropriate screening methods remains crucial.

Nationwide’s coordinators utilize an assessment tool that evaluates children as they work through a book during their medical appointments — available in both English and Spanish. Staff needed time to perfect the timing, learning to avoid periods right after vaccinations when children might be distressed, but the reading evaluations typically require just 10 minutes.

Following each assessment, coordinators develop individualized literacy plans that identify specific areas requiring additional practice.

These appointments also allow staff to demonstrate activities parents can implement at home, such as reading stories aloud, according to Carneshia Edwards, who oversees the hospital’s kindergarten readiness initiative.

“When we’re doing the screenings, families are kind of concerned that their kids don’t know certain things and it’s not necessarily about that piece of it,” Edwards noted. “It’s just more so exposing them more than anything.”

Before 3-year-old Juri Sleet underwent her literacy evaluation, her grandmother Quintina Davis was concerned that Juri lacked sufficient early learning experiences. However, working with the literacy coordinator at their clinic helped Davis discover numerous activities she could pursue at home with Juri.

“She didn’t know as much, but our coordinator was very patient with her,” Davis shared.

After completing screenings, coordinators assemble literacy packages containing various tools and activities for home practice. These materials are also shaped by input from Columbus City Schools educators regarding what skills students need when entering kindergarten.

The package contents depend largely on program donations. Common items include dry-erase boards for letter writing and books for reading practice. However, the kits might also contain safety scissors or pencils with rubber grips to enhance fine motor abilities.

“Parents are the first teachers, so we really try to encourage them to sit down with their child and just kind of work with them before going into kindergarten,” Edwards emphasized.

Coordinators maintain contact with families they’ve worked with, sometimes connecting children to early education initiatives like the federally-supported Head Start preschool program or SPARK, which provides educational home visits.

When children return for clinic visits a year later, coordinators meet with them again. For Juri, now 4 years old, the follow-up appointment demonstrated how much progress she had achieved over twelve months, her grandmother reported.

During that year, Juri had improved significantly in identifying letters, sounds, and sight words. With her literacy coordinator’s assistance, Juri also began attending preschool at a nearby YMCA, Davis explained. She’s been performing “awesome” there, Davis said, and she’s excited to watch her continue developing.

“The goal is to make sure by the time she starts kindergarten, that she’s absolutely ready without having a lot of challenges,” Davis stated. “So right now, I think she is heading towards that way.”

A unique California medical program that delivers the globe’s only treatment for life-threatening infant botulism brings hope to devastated families in an unexpected way – whimsical birthday cards celebrating their children’s first year of life.

Each year, employees at California’s Infant Botulism Treatment and Prevention Program create and send approximately 200 handmade cards to honor the recovery of youngsters who battled this uncommon and serious illness.

Recently, this recipient list has expanded to include many American infants impacted by a botulism outbreak linked to tainted ByHeart baby formula.

Amy Mazziotti from Burbank, California, was among those who received a birthday greeting for her son Hank this past September, following his 12-day hospital stay after consuming the contaminated ByHeart formula.

“The fact that they take the time to send hand-drawn cards to each baby is incredibly special,” Mazziotti expressed. “When you’re worried about your baby, it’s the small acts like this that somehow feel really big.”

Robin Hinks, a program assistant, oversees the card initiative, handling everything from artwork to distribution and record-keeping.

“I am a big fan of drawing animals with party hats,” Hinks explained, describing her preference for crayons and colored pencils. “Like, here’s a frog with some balloons and a little penguin.”

While the program’s main mission focuses on diagnosing and treating this condition that develops when infants consume botulism spores that grow in their intestines and create a harmful toxin affecting the nervous system and causing paralysis, the personal touch matters greatly. Mortality rates previously reached 90%, but proper treatment has reduced deaths to under 1%.

The exclusive treatment, called BabyBIG, consists of an intravenous medicine created from combined blood plasma of adults who received botulism immunizations. California’s program serves as the worldwide supplier.

Given the rarity of this disease, affecting roughly 200 children annually, the botulism center has evolved into a vital resource and support network for families navigating this difficult experience.

“Support of the babies and their families remains paramount to our program and our mission,” stated Dr. Jessica Khouri, the program’s senior medical officer.

Heather Goody from Gallipolis, Ohio, remembered feeling isolated when her daughter MaryEllen developed infant botulism in 2016. Almost ten years later, Goody continues managing a Facebook community called Infant Botulism Awareness, connecting parents of affected children. The group now includes over 500 members.

She vividly remembers the emotional impact of receiving MaryEllen’s first birthday card.

“It brought all the feels, but most importantly the feeling of gratitude that she was thriving in all areas of life,” Goody recalled.

This ongoing relationship was championed by the late Dr. Stephen Arnon, who alongside his team in 1976 discovered this specific type of botulism affecting infants under one year old, then dedicated the following 45 years to developing effective treatments.

Arnon, who passed away in 2022, maintained regular contact with families of children affected by infant botulism, keeping them informed as his research advanced.

Currently, almost 1,500 families belong to the botulism program’s parent community, including children who received treatment twenty years ago. Members celebrate everything from preschool milestones to college admissions and other significant achievements.

“Former patients have gone on to have families of their own and keep in touch with us,” Khouri noted. “It really is an incredible part of the work we do.”

The Centers for Disease Control and Prevention announced this week that its vaccine advisory committee will convene on March 18, according to information posted on the agency’s official website.

The scheduled meeting was confirmed in an update published Tuesday on the CDC’s online platform.

BANGKOK — Thai health authorities announced Tuesday that the deaths of 72 tigers at two northern Thailand tourist attractions resulted from canine distemper virus, not bird flu, easing public health concerns about human transmission.

The tiger deaths occurred over approximately 10 days from February 8-18 at animal parks located in Mae Taeng and Mae Rim districts within Chiang Mai province.

“There has not been an animal-to-human infection case,” Public Health Minister Pattana Promphat stated during a Bangkok news conference at Government House.

Laboratory examinations conducted by the Chiang Mai regional livestock office revealed genetic material from canine distemper virus and bacterial infections in the deceased animals, but confirmed no presence of avian influenza type A virus, commonly called bird flu.

Health officials continue monitoring individuals who recently handled the tigers, though no symptoms have appeared among staff or visitors so far.

“If we detect any sick persons, we will prepare for a nationwide monitoring measure,” explained Monthien Khanasawat, who leads the Public Health Ministry’s Disease Control Department. “This will include contact tracing and treatment as necessary.”

The announcement appeared designed to calm public fears about bird flu, which has resurged across parts of Asia. Between 2004 and 2007, Thailand recorded 17 fatalities among 25 people infected with poultry-related influenza, according to ministry data.

Canine distemper virus affects both dogs and cats, but produces more severe symptoms in large felines like tigers. The infection spreads through bodily fluids and airborne transmission. Thai officials noted that tigers in captivity face heightened vulnerability due to stress and inbreeding conditions.

Livestock Development Department Director-General Somchuan Rattanamangklanan reported that all tiger remains underwent complete necropsies before cremation and burial. Workers properly disinfected, photographed and disposed of carcasses to prevent any unauthorized use.

However, veterinarian Visit Arsaithamkul, who participated in the post-mortem examinations, raised concerns about the infection’s unclear origins. Through a Facebook post, he suggested that contaminated food from a shared supplier might explain the outbreak, given that both facilities sit just 30 kilometers apart.

When contacted for additional details, Arsaithamkul declined further comment. Both attractions, operating under the Tiger Kingdom brand, remain temporarily closed. Park operators have not responded to requests for statements.

Thai health officials maintain vigilance regarding potential bird flu threats. Monthien advised citizens to exercise caution with poultry consumption after an unnamed neighboring country reported a human bird flu infection.

Bird flu first jumped from animals to humans in Hong Kong during 1997, followed by a pandemic that spread throughout Asia beginning in 2003. Thailand’s previous outbreak led to the destruction of tens of millions of birds and dramatically reduced poultry consumption due to infection fears.

A bite from the Lone Star tick can trigger Alpha-Gal syndrome, a condition that leads to an allergic reaction to red meat. These ticks have spread throughout several regions of the United States, including the Northeast, South, mid-south, and Midwest areas, typically inhabiting forested locations with thick vegetation and undergrowth.

University of Missouri extension educator Eden Stewart explains that understanding the symptoms is crucial, though not every tick bite will result in developing this meat allergy condition.

A specialized program based in San Francisco has been dedicated to helping nervous passengers overcome their aviation phobias for half a century.

The clinic offers a comprehensive four-day training program designed to support individuals who struggle with flight anxiety. As part of the therapeutic process, participants get hands-on experience with actual aircraft, including walking up boarding steps and entering a Boeing 787.

The program focuses on gradual exposure to aviation environments, allowing anxious travelers to become familiar with the sounds and visual elements of air travel in a controlled, supportive setting. This approach helps participants build confidence before taking actual flights.

The long-running initiative has provided a safe space where people with flight phobias can work through their fears with professional guidance and peer support from others facing similar challenges.

Danish pharmaceutical giant Novo Nordisk announced Tuesday that an experimental obesity medication developed in partnership with United Biotechnology produced remarkable weight reduction results during clinical testing.

The investigational drug, known as UBT251, works by targeting three different hormone receptors – GLP-1, GIP, and glucagon – and led to an average weight loss of nearly 20% among study participants over a six-month period, according to the company’s announcement.

United Biotechnology conducted the clinical trial to evaluate both the safety profile and effectiveness of the weekly injection treatment. Researchers tested three different dosage levels – 2 milligrams, 4 milligrams, and 6 milligrams – against a placebo in Chinese participants who were either overweight or obese.

Study participants began the trial with an average body weight of 92.2 kilograms (approximately 203 pounds). Those receiving the highest dose of UBT251 experienced a maximum average weight reduction of 19.7%, while participants given the placebo only lost 2.0% of their body weight during the same 24-week treatment period, Novo Nordisk reported.

The results represent a statistically significant difference between the treatment and control groups, marking another potential breakthrough in obesity treatment development.

OAKLAND, Calif. — Roughly 31,000 healthcare workers at Kaiser Permanente facilities in California and Hawaii will clock back in on Tuesday, bringing their month-long work stoppage to a close as union leaders report meaningful progress in contract talks.

The United Nurses Associations of California/Union of Health Care Professionals announced Monday that “significant movement at the bargaining table” led to their decision to suspend the walkout. Union officials have not revealed specifics about what breakthroughs occurred during recent negotiations or outlined terms of any preliminary agreement.

“According to the union, returning members to their patients and their livelihoods is the clearest path to securing a final agreement and building on the progress achieved during the strike,” the organization stated.

Kaiser Permanente management has not yet responded to the union’s announcement about ending the work stoppage.

The labor action, which launched on January 27, represents the second significant strike by this union in recent months. Workers previously walked off the job for five days in October, leading to resumed talks that ultimately stalled in December.

Striking employees, including pharmacists, midwives and rehabilitation therapists, argued their compensation has failed to match rising costs of living while understaffing issues prevent adequate patient care.

Union members sought a 25% pay boost spread across four years, claiming their current wages lag behind comparable positions by at least 7%.

The healthcare giant had offered a 21.5% raise over the same timeframe. Company representatives argued their unionized staff already earns 16% more than industry counterparts on average, and meeting striker demands would force higher costs onto patients.

Medical facilities stayed operational throughout the strike, though some face-to-face appointments moved to telehealth platforms and certain non-urgent procedures were postponed.

Based in Oakland, Kaiser Permanente runs one of America’s biggest nonprofit healthcare networks, providing services to 12.6 million patients across 600 medical facilities and 40 hospitals, primarily in western states.

Meanwhile in New York City, nurses at NewYork-Presbyterian Hospital system voted Saturday to accept a new contract, ending their own strike that lasted over a month.

Two additional major New York hospital networks, Montefiore and Mount Sinai, resolved their nursing strikes earlier this month through contract deals with the same union.

Israeli health authorities disclosed Monday that roughly 50% of vegetables imported from Palestinian territories contain toxic chemical residues at dangerously elevated concentrations.

During a Knesset Health Committee session, officials reported that approximately 15,000 tons of agricultural products enter Israel annually from these regions, with significant contamination detected across multiple vegetable varieties.

Ziva Hamma, who leads the Health Ministry’s Food Risk Management Department, informed committee members that current testing protocols allow produce shipments to reach markets before laboratory analysis results become available.

According to reporting by The Jerusalem Post, the Coordinator of Government Activities in the Territories announced plans to implement an eight-month suspension period following discoveries that contamination rates reached 50% for cucumbers, 49% for tomatoes, and 66% for hot peppers from Palestinian Authority regions.

The new suspension protocol would require all produce to remain warehoused until testing confirms pesticide levels meet safety standards.

Laboratory analysis revealed that 13% of tested produce contained more than five different chemical pesticides, while 14% of samples showed presence of organophosphates – neurotoxic compounds associated with developmental risks in fetuses, infants, and children, as well as increased Parkinson’s disease risk.

Samir Maadi, Agricultural Coordinator at the Civil Administration, explained that contaminated produce gets removed from sale immediately, with responsible farmers facing temporary market exclusion. Among approximately 3,000 farmers in the program, several hundred have faced disqualification. Banned producers may return to selling after three months, provided they pass subsequent inspections.

MK Amit Halevi from the Likud party criticized the situation, stating: “The data provided by the Health Ministry itself shows that the food of Israeli citizens is poisoned, and the Coordinator of Government Activities’ considerations should not influence the ministry’s decisions.”

Halevi further commented: “Israeli citizens have been suffering from cancer for years because of this produce and the Health Ministry remains silent. Employees of the Ministries of Agriculture and Health have failed in their duties and their mission and obeyed the Civil Administration to poison the citizens.”

The lawmaker also encouraged individuals who developed cancer potentially linked to contaminated produce consumption to pursue legal action against Civil Administration leadership who approved the import procedures.

WASHINGTON — Federal health regulators unveiled plans Monday for a streamlined approval process designed to accelerate the development of personalized treatments for patients battling uncommon medical conditions, particularly rare genetic disorders that pharmaceutical companies have historically avoided due to limited profit potential.

The draft Food and Drug Administration framework would establish a fresh regulatory route for individualized therapies that have undergone testing in only small patient groups, given the difficulties of conducting extensive clinical studies. While the FDA’s announcement highlighted gene editing technologies, agency leaders indicated the new framework could apply to various other treatments and medications.

This represents a transformation that patient groups, advocates, and researchers specializing in uncommon diseases have pursued for years, as these conditions typically don’t align with standard pharmaceutical business models or the FDA’s conventional approval procedures.

“It is our priority to remove barriers and exercise regulatory flexibility to encourage scientific advances and deliver more cures and meaningful treatments for patients suffering from rare diseases,” FDA Commissioner Marty Makary said in a release.

The development follows Makary’s announcement last week that the FDA would eliminate its longstanding requirement for two clinical trials in standard drug evaluations. This marks another modification to FDA protocols and guidelines, many implemented without following traditional federal procedures for updating agency regulations.

Top FDA officials emphasized that these recent modifications, including Monday’s proposed pathway, don’t represent entirely new FDA policies. The agency will accept public feedback on its preliminary guidance for 60 days before moving toward finalization.

Academic scientists have recently demonstrated their ability to utilize cutting-edge technology to fix specific genetic defects in individual patients. In the previous year, researchers at Children’s Hospital of Philadelphia and the University of Pennsylvania created a treatment using CRISPR, the Nobel Prize-recognized gene editing technology, to help an infant born with an uncommon condition causing dangerous ammonia accumulation in the bloodstream.

Under current procedures, the FDA mandates that pharmaceutical companies prove their experimental treatments are both safe and effective through clinical studies comparing patient groups receiving the therapy against those given placebo treatments or alternative interventions. Larger patient enrollment typically produces more reliable evidence.

However, for medical conditions affecting only a small percentage of the global population, drug manufacturers frequently lack motivation to invest the millions required to complete studies and navigate the FDA approval process, which can extend beyond a decade.

Monday’s announced pathway would establish a uniform process for authorizing experimental treatments while importantly providing companies opportunities to market these therapies commercially.

The FDA currently permits experimental drug use through “compassionate use” programs for individuals with no alternative treatment options. However, this process proves difficult to navigate and strictly prevents companies or researchers from earning profits on treatments not yet approved by the FDA.

The new pathway’s designation — plausible mechanism — refers to the standards FDA regulators will demand before approving any experimental therapies.

FDA officials indicate this approach will be limited to well-understood conditions where reasonable evidence suggests the therapy will target the disease’s underlying genetic or cellular mechanisms. Researchers must also verify that the therapy successfully addressed the patient’s specific genetic or biological abnormality.

New research shows that vaccination rates for hepatitis B in American newborns were already falling significantly before federal health officials officially changed their guidance last December.

A study published Monday in JAMA found that the percentage of babies receiving hepatitis B shots within their first month of life dropped by more than 10 percentage points from 2023 to 2025.

For decades, vaccination rates had been steadily increasing as the federal government supported giving newborns their first hepatitis B shot shortly after delivery. However, under Health Secretary Robert F. Kennedy Jr., the Centers for Disease Control and Prevention recently modified its recommendation, now only advising the vaccine when mothers are infected with the virus or their infection status is unclear.

Hepatitis B is a serious virus that damages the liver and represents the primary cause of liver cancer globally. While most adults can fight off the infection naturally, it becomes a lifelong condition in over 90% of infected babies and up to half of young children who contract it.

Government health records demonstrate that newborn vaccination reduced hepatitis B cases among American children by almost 90% following the 1991 recommendation for birth doses.

“If the rates of vaccination decline too significantly, we may see a resurgence in hepatitis B infections in infants and children,” said study leader Dr. Joshua Rothman, a pediatrician at the University of California, San Diego.

JULY 2023 TURNING POINT

The researchers found that vaccination rates began dropping in July 2023, a time that matched increased public discussion and news coverage about childhood immunizations.

During this timeframe, vaccine skeptic Kennedy appeared on a popular Joe Rogan Experience podcast episode that received widespread attention, according to the study authors.

Kennedy, President Donald Trump, and other prominent figures have made claims linking childhood vaccines to autism, despite scientific evidence showing no such connection. Federal authorities have withdrawn recommendations for six different childhood vaccines over the past year.

The study tracked vaccination data from 2002 through 2025, covering more than 12 million births through Epic Systems Corp records. From 2002 – three years before official guidelines recommended medically stable newborns receive the vaccine before leaving the hospital – until 2023, birth-dose vaccination rates climbed from approximately 21% to 83.5%.

By August 2025, that figure had decreased to 73.2%, the analysis showed.

In December 2025, an advisory committee selected by Kennedy eliminated the long-standing recommendation. The panel determined that when mothers test negative for hepatitis B, parents should work with their physicians to decide if and when their children should receive hepatitis B vaccines.

The advisors, many sharing Kennedy’s vaccine-critical perspective, presented no new evidence of harm from the immunization. Instead, they contended that widespread vaccination was excessive given infection risks. The CDC, which Kennedy oversees, quickly adopted this position.

Medical experts have cautioned that this policy shift could undermine decades of public health achievements.

Rothman noted he hasn’t seen research yet documenting increased infection cases.

“The reason pediatricians and the American Academy of Pediatrics still recommend the birth dose for all newborns is that it serves as a safety net,” Rothman said.

“If the maternal test ends up being a false negative, if there’s an unexpected household or caregiver exposure, or if the infant’s follow-up is delayed, this birth dose provides early protection.”

WASHINGTON – Federal health officials on Monday unveiled a new regulatory approach designed to accelerate the approval process for customized genetic treatments targeting rare, life-threatening conditions, permitting pharmaceutical companies to use smaller, tightly controlled research studies when conventional large-scale trials aren’t practical.

The initiative seeks to modernize approval criteria for personalized genetic medications, establishing a route for treatments designed for patient populations too limited in size for standard clinical trials.

This approach could grant patients faster access to potentially life-saving therapies that might otherwise become stalled due to insufficient data collection capabilities, while maintaining safety oversight through post-market monitoring requirements.

The regulatory framework provides pharmaceutical manufacturers with more definitive guidelines for creating genome-modification and RNA-based medications, while mandating they demonstrate why traditional randomized studies aren’t workable, gather real-world data following approval, and conduct confirmatory research for expedited authorization. Federal regulators cautioned they reserve the right to remove products from the market if follow-up studies prove unsuccessful or remain incomplete.

This draft guidance, initially presented in November, would enable companies to pursue approval using preliminary effectiveness indicators and a treatment’s scientific foundation, instead of requiring comprehensive randomized clinical trials. The framework encompasses genome-editing and RNA-based treatments, with potential expansion to additional precision therapies.

Companies would continue collecting real-world data post-approval to validate effectiveness and track safety, while ensuring patient safeguards including informed consent and independent review board supervision.

Regulators emphasized the importance of early collection of baseline and disease progression data. For treatments addressing various mutations within identical genes, they suggested observational research and coordinated protocol structures to enable data sharing among similar products.

“We anticipate that we’re going to get a flood of applications for treatments of rare diseases,” a senior FDA official told reporters.

Production standards would stay the same, though manufacturers may utilize previous experience and proven methodologies to expedite development timelines.

The Centers for Disease Control and Prevention announced Monday that Ralph Abraham has resigned from his role as Principal Deputy Director, with the departure taking effect immediately due to unexpected family commitments.

CDC officials have not yet disclosed who will fill Abraham’s position following his sudden resignation.

The departure comes amid ongoing leadership transitions within the nation’s top health agencies. Jay Bhattacharya, who leads the National Institutes of Health, has taken over as the CDC’s acting director as part of broader reorganization efforts within the health department during this election period.

Jim O’Neill, a Deputy Security official with Health and Human Services who had been leading the CDC in an acting capacity since August, left both of his positions earlier this month.

Pharmaceutical company Eli Lilly announced Monday that federal regulators have given the green light for a new delivery system for its popular weight-loss medication Zepbound. The FDA-approved four-dose KwikPen provides patients with an entire month’s worth of treatment in one convenient device.

This development puts Lilly ahead of competitor Novo Nordisk, whose Wegovy weight-loss treatment has been available in the United States as a single-dose weekly injection pen since 2021.

The new Zepbound KwikPen will carry a starting price of $299 monthly for patients paying out of pocket, specifically for the 2.5-milligram dosage. The multi-dose injection device will come in six different strength options: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

Lilly already uses the KwikPen technology for delivering Mounjaro, its diabetes medication. The device has been available in several major international markets including the United Kingdom, Australia, Middle Eastern countries, and Canada.

The FDA gave Zepbound its approval in 2023, and the medication is currently offered in the United States through single-dose autoinjectors and vials. According to prescription data, Zepbound has surpassed Novo Nordisk’s Wegovy to become the leading weight-loss treatment in the American market.

For years, Lori Sepich was a smoker who occasionally forgot to take her blood pressure medication. Despite these risk factors, the thought of experiencing a heart attack never crossed her mind.

“It just wasn’t registering with me,” explained the 64-year-old Memphis resident, who has endured two heart attacks spanning 13 years.

Sepich’s experience reflects a widespread reality affecting millions of American women. Cardiovascular disease impacts over 60 million women nationwide, encompassing conditions such as heart disease, stroke, heart failure, and atrial fibrillation. Contrary to popular belief that heart attacks primarily affect men, women face significant vulnerability as well.

Statistics reveal that cardiovascular disease claims the lives of one in five American women annually, with 37,000 deaths specifically attributed to heart attacks.

“Cardiovascular disease stands as the leading cause of death among women. It will impact either you or someone close to you,” explained Dr. Sharonne Hayes, a cardiologist practicing at Mayo Clinic in Rochester, Minnesota. “Understanding heart attack warning signs and responding appropriately is crucial.”

Multiple strategies exist for reducing cardiovascular risks.

The American Heart Association developed guidelines known as “Life’s Essential 8,” which include: improving diet quality, eliminating tobacco use, achieving quality sleep, increasing physical activity, managing cholesterol levels, and controlling weight, blood sugar, and blood pressure.

Association president Dr. Stacey Rosen recommends scheduling routine medical appointments to address these prevention strategies, monitor overall health, and review any family history of cardiac issues.

Medical professionals also emphasize discussing risk factors that specifically or disproportionately impact women.

Women face higher rates of autoimmune disorders such as lupus and rheumatoid arthritis, conditions that trigger inflammation and potentially elevate heart disease risk. Additionally, women experience depression more frequently, which correlates with inflammation and harmful behaviors like prolonged bed rest.

Additional conditions linked to increased cardiovascular disease risk include pregnancy-related high blood pressure or diabetes, pregnancy loss, and stillbirth. Menopausal symptoms like hot flashes and night sweats have also been connected to elevated blood pressure and other cardiovascular risk factors.

Popular culture often portrays heart attacks as middle-aged men suddenly grasping their chest before collapsing.

However, Hayes notes that reality differs significantly: “It’s probably not going to resemble those dramatic Hollywood heart attacks.”

While chest pain or discomfort represents a typical symptom, many other warning signs exist.

“Women tend to experience additional symptoms more frequently than men,” Rosen noted.

These alternative symptoms encompass back pain, breathing difficulties, cold sweats, fatigue, nausea, dizziness, anxiety, jaw discomfort, and finger tingling.

Medical researchers haven’t definitively determined why symptom patterns vary between genders, though some studies indicate that biological differences may contribute to these variations.

Another distinction involves symptom onset: women may experience more gradual symptom development compared to men. Hayes frequently hears similar accounts from patients: “Symptoms appeared and fluctuated somewhat over time, but I sensed something was wrong.”

“When you suspect even the slightest possibility of a heart attack, immediately call 911,” Rosen advised, emphasizing that “it’s preferable to overreact rather than dismiss something potentially life-threatening.”

Medical experts recommend ambulance transportation to hospitals, which possess superior emergency response capabilities compared to urgent care facilities or physician offices.

Treatment delays can result in serious harm or death.

“Extended delays can lead to more severe damage,” Rosen warned.

During her initial heart attack, Sepich delayed seeking treatment too long. She had largely ignored her cardiac health issues since receiving a diagnosis of severe, hereditary high blood pressure at age 17.

Easter Sunday 2005 brought intense chest pressure, nausea, and pain spreading down her arms.

“I deliberately ignored those warning signs because I was completely shocked,” she recalled. “Fear overwhelmed me.”

She proceeded with church services and family gathering, then reported to work the following day. Eventually, her physician’s insistence led her to the emergency room, where she received six stents and remained hospitalized for one week.

Her response improved during her second heart attack, resulting in another stent placement after her cardiologist discovered nearly complete blockage in the heart’s main artery.

Today, Sepich maintains controlled blood pressure, hasn’t smoked for over twenty years, and exercises nearly daily.

She encourages other women to acknowledge heart disease risks honestly.

“Denial allowed me to rationalize my behavior. I could think, ‘This won’t harm you,’” Sepich reflected. “But it does cause harm. It can be fatal.”

A growing number of people are developing a unusual food allergy that prevents them from eating red meat, and it’s all because of tick bites.

The condition, known as alpha-gal syndrome, occurs when individuals become allergic to a sugar molecule called alpha-gal that exists in mammalian meat. According to Eden Stewart, who works as a Field Specialist in Nutrition and Health education at the University of Missouri, the syndrome develops after being bitten by a Lone Star tick.

Medical experts are reporting an increase in diagnosed cases of this meat allergy across the country. The University of Missouri Extension recently published information to help people better understand this emerging health concern.

The syndrome can cause serious allergic reactions when affected individuals consume beef, pork, lamb, and other mammalian products, making it a significant dietary and health challenge for those diagnosed.

Tens of millions of Americans experience aerophobia, a condition characterized by intense anxiety about air travel. For the past five decades, a specialized Bay Area program has dedicated itself to helping nervous passengers conquer their fears and board aircraft with confidence.

The California-based clinic has been providing support and treatment to travelers who find themselves gripped by fear at the thought of flying, offering them tools and techniques to overcome their aviation anxiety and navigate air travel successfully.

HARARE, Zimbabwe — In a dusty area outside Zimbabwe’s capital city, dozens of young women, mothers carrying infants, and men gathered in lines Thursday to receive doses of a revolutionary HIV prevention medication that requires just two injections annually.

The southern African nation, which has experienced tens of thousands of HIV-related fatalities over the last twenty years, has become among the initial countries to distribute lenacapavir, an extended-release medication that officials believe will reduce new infection rates.

Clinical trials have shown the treatment provides nearly complete protection, leading some medical experts to call it a game-changer for vulnerable populations. However, others caution that transforming this scientific breakthrough into widespread success will depend on addressing funding limitations, healthcare system weaknesses, and maintaining patient participation.

Following her injection at the Zimbabwe launch event, Constance Mukoloka emerged from a mobile healthcare unit with a bright smile of relief after becoming one of the initial recipients.

“I am safe, I can work with confidence now,” the 27-year-old sex worker explained, discussing how taking daily preventive pills for preexposure prophylaxis, known as PrEP, frequently caused problems with clients and was hard to maintain regularly — endangering herself and others.

Mukoloka represents one of the earliest recipients of a donor-funded lenacapavir distribution program spanning 10 African nations. Medical authorities and advocates believe this medication could transform HIV prevention approaches if governments can overcome obstacles related to expenses and vulnerable healthcare infrastructure.

Created by Gilead Sciences in California, the introduction of lenacapavir in targeted high-risk nations receives backing from the United States President’s Emergency Plan for AIDS Relief, known as PEPFAR, working alongside the Global Fund.

Zimbabwe provides the injection at no cost to vulnerable groups including sex workers, teenage girls and young women, gay men, and expectant or nursing mothers.

For Mukoloka, this treatment means far more than simple convenience.

“When I took tablets, customers would see a container of pills and leave. They would never return due to fear,” she explained. “They couldn’t tell the difference between PrEP and treatment drugs. With the work we do, that stigma costs you money.”

Zimbabwe has offered daily oral PrEP for years along with condoms, vaginal rings, and shorter-duration injections. Still, consistent use has remained problematic, especially for individuals experiencing stigma or irregular routines.

“I work in beer halls looking for clients. Sometimes I would get drunk and forget to take my drugs,” Mukoloka noted. “Sometimes I would work all night and not have time. Some clients refuse protection. They say … ‘Why should I use protection when I have paid?’”

Medical officials view lenacapavir’s subtle nature and lengthy effectiveness as crucial benefits for key groups like sex workers, making it valuable in combating HIV transmission.

“Prevention must fit into real life. If a health solution is too complicated, too demanding, or too visible, people simply won’t use it,” stated Douglas Mombeshora, Zimbabwe’s health minister, during Thursday’s launch ceremony. “Lenacapavir represents a new way of doing things.”

Other southern African countries including Zambia and Eswatini have also introduced the medication.

Zimbabwe, Eswatini, and Zambia, formerly major HIV hotspots worldwide, have become leading examples of epidemic management in recent years, meeting World Health Organization goals for testing, treatment, and viral suppression.

Despite these achievements, new infections continue causing concern, especially among teenage girls and young women.

The United Nations children’s agency reports that HIV rates among adolescent girls and young women aged 10-24 remain “persistently” three times higher than their male peers in sub-Saharan Africa, caused by gender inequality, poverty, and unequal healthcare access.

Throughout sub-Saharan Africa, females of all ages represented 63% of new HIV infections in 2024, according to UNAIDS. In other global regions, approximately 73% of new 2024 infections affected males.

Zimbabwean authorities expect roughly 46,000 individuals across 24 locations to receive treatment during lenacapavir’s initial rollout phase, representing a small portion of potential need in this country of approximately 15 million residents.

Plans for subsequent phases remain unclear. Government officials express hope that beneficiary numbers will grow as additional donor-funded supplies become available. They also aim to purchase their own doses for broader distribution but, like many African governments, face insufficient funding.

Medical professionals, experts, and activists caution that real-world challenges could limit the drug’s early potential across Africa, a continent exceeding 1.5 billion people, particularly due to expensive mass distribution costs for governments.

Kenya, which received its initial 21,000 lenacapavir doses this week, announced the injection would cost approximately $54 per person annually at negotiated rates, still representing a substantial expense for many.

Gilead Sciences has committed to selling its medication without profit to low and middle-income countries significantly affected by HIV.

Bellinda Thibela, who focuses on health justice and access at Health GAP, an international advocacy group, called this move “a bit comforting” but insufficient alone on a continent where healthcare systems depend heavily on declining external funding, particularly following President Donald Trump’s foreign aid reductions.

Difficulties will persist in nations that were “80% to 90% dependent on U.S. funding,” Thibela observed. “What’s the point of having a reduced price if there is no staff and equipment in clinics?”

While numerous medical professionals consider lenacapavir a major advancement, they emphasize it should supplement, not substitute, existing prevention methods.

“Condoms remain key. They are cheap and they also prevent other sexually transmitted infections,” explained Enerst Chikwati, Zimbabwe program director at AIDS Healthcare Foundation.

However, for early users like Mukoloka, the medication’s effects already seem transformative.

“I am elated. I can go for a whole six months feeling safe,” she said.

A significant nursing strike affecting New York City hospitals has officially concluded after nurses at NewYork-Presbyterian approved their new employment agreement on Saturday, bringing an end to labor action that lasted more than a month.

The walkout began January 12th when over 4,000 nurses employed by the private NewYork-Presbyterian hospital network left their posts. These healthcare workers are scheduled to resume their duties in the upcoming week following the contract approval by the New York State Nurses Association, where 93% of union members voted in favor of the three-year agreement.

Earlier this month, nurses at two additional major private hospital networks – Montefiore and Mount Sinai – concluded their own labor disputes by reaching contract settlements with the identical union organization.

“We are so happy with the wins we achieved, and now the fight to enforce these contracts and hold our employers accountable begins,” union President Nancy Hagans said in a statement Saturday.

Hospital administrators at NewYork-Presbyterian expressed anticipation for their nursing staff’s return, stating the agreement “reflects our respect for our nurses and the critical role they play as part of our exceptional care teams.”

Representatives from both the union and hospital management announced Friday they had achieved a preliminary agreement. Union membership conducted voting on the proposal Friday and Saturday.

The approved contract contains enhanced staffing measures, wage increases exceeding 12% across the three-year term, and protective measures concerning artificial intelligence implementation, the union reported.

According to union officials, the initial strike encompassed approximately 15,000 nursing professionals across the Montefiore, Mount Sinai and NewYork-Presbyterian systems. The work stoppage impacted select facilities within these three networks and did not include any municipally-operated hospitals.

Throughout the strike period, all three hospital systems – Montefiore, Mount Sinai and NewYork-Presbyterian – hired thousands of replacement nursing staff, relocated certain patients to other facilities, and postponed non-essential medical procedures. Hospital leadership maintained they continued providing quality patient care, including complicated surgical operations. However, some patients requiring additional assistance and their family members reported delays in basic care tasks.

The striking nurses cited overwhelming patient loads and alleged the hospitals were attempting to reduce health insurance benefits. Hospital administrators disputed these accusations and characterized the union’s contract demands as unreasonable.

Nursing staff at certain Mount Sinai and Montefiore locations previously conducted a work stoppage in 2023, which concluded after three days.

Experts are drawing parallels between excessive social media use and addictive substances like gambling, drugs, and tobacco products.

Although mental health professionals continue debating where normal usage ends and problematic behavior begins, there’s widespread agreement that countless individuals feel trapped by platforms like Instagram, TikTok, and Snapchat.

These tech companies have financial motivations to maximize user engagement, generating billions through targeted advertising. Fighting against endless feeds, dopamine-triggering short videos, and the validation from likes and comments can feel overwhelming. Some users also find themselves drawn to controversial content, negative news cycles, and online arguments.

While much attention has centered on young people’s social media habits, adults face similar risks when platform usage begins disrupting their daily routines.

Stanford University School of Medicine’s Dr. Anna Lembke, who serves as medical director of addiction medicine, describes addiction as “the continued compulsive use of a substance or behavior despite harm to self or others.”

During testimony at a significant social media litigation case in Los Angeles, Lembke explained that these platforms become addictive due to the “24/7, really limitless, frictionless access” users maintain.

However, some researchers challenge using “addiction” to describe heavy social media consumption, insisting true addiction requires identifiable symptoms like intense cravings and withdrawal effects.

The Diagnostic and Statistical Manual of Mental Disorders doesn’t officially recognize social media addiction, partly because professionals lack consensus on defining it and understanding how existing mental health conditions contribute to excessive use.

Despite this diagnostic uncertainty, many experts believe problematic social media consumption can still cause real harm.

“For me, the biggest signpost is how does the person feel about the ‘amount,’ and how viewing it makes them feel,” explained Dr. Laurel Williams, a psychiatry and behavioral sciences professor at Baylor College of Medicine. “If what they discover is they view it so much that they are missing out on other things they may enjoy or things that they need to attend to, this is problematic use. Additionally, if you leave feeling overwhelmed, drained, sad, anxious, angry regularly, this use is not good for you.”

Key warning signs include neglecting responsibilities, hobbies, or relationships in favor of scrolling, unsuccessful attempts to reduce usage, and negative feelings about your social media habits.

University of Melbourne professor Ofir Turel, who researches social media behavior, acknowledged there’s “no agreement” on defining social media addiction and doesn’t “expect agreement soon.”

“It’s obvious that we have an issue,” Turel noted. “You don’t have to call it an addiction, but there is an issue and we need, as a society, to start thinking about it.”

Williams recommends understanding how social media algorithms and advertising target users before attempting to limit usage.

“Think of social media as a company trying to get you to stay with them and buy something — have the mindset that this is information that I don’t need to act on and may not be true,” she advised. “Get alternate sources of information. Always understand the more you see something, anyone can start to believe it is true.”

California Institute of Technology postdoctoral scholar Ian A. Anderson suggests starting with minor adjustments to prevent automatic app opening. Relocating apps on your phone or disabling notifications are “light touch interventions,” while more comprehensive approaches might include keeping phones out of bedrooms or other frequent-use areas.

Built-in technology features can help manage screen time on both iPhone and Android devices.

iPhone users can access Screen Time controls through their settings menu, allowing them to establish Downtime periods that disable phone functions during chosen hours.

These controls enable users to restrict entire app categories like social media, games, or entertainment, or target specific applications with time limits.

However, these restrictions are relatively easy to bypass, functioning more as gentle reminders than absolute barriers. When attempting to open restricted apps, users receive options for additional minutes, delayed reminders, or complete override.

When gentle approaches prove insufficient, more aggressive strategies may be necessary. Some users report success switching their phones to grayscale mode, making screens less appealing to dopamine-seeking brains. iPhone users can adjust color filters in settings, while Android users can activate Bedtime Mode or modify color correction settings. Switching to basic flip phones represents another option for curbing social media impulses.

Several startups offer physical barriers between users and their apps. Unpluq provides a yellow tag that must be held against phones to access blocked applications. Brick and Blok function similarly, requiring users to tap or scan square plastic devices to unlock apps.

For more extreme measures, various phone lockboxes and cases are available, including products originally designed for parents managing teenagers’ device usage.

Yondr, known for phone-locking pouches used at concerts and schools, also manufactures home phone storage boxes.

When technological solutions fail, examining underlying causes for social media dependency might be beneficial. Excessive usage could indicate deeper issues like anxiety, stress, isolation, depression, or confidence problems. In such cases, therapy options are becoming increasingly accessible.

“For people struggling to stay away — see if you can get a friend group to collaborate with you on it. Make it a group effort. Just don’t post about it! The more spaces become phone free, the more we may see a lessened desire to be ‘on,’” Williams concluded.

Federal health regulators have given the green light to a new psychiatric medication developed by Vanda Pharmaceuticals, marking another treatment option for patients with severe mental health disorders.

The pharmaceutical company announced Friday that the Food and Drug Administration has cleared their drug for treating two serious psychiatric conditions, though specific details about the conditions were not disclosed in the initial announcement.

The approval represents a significant milestone for Vanda Pharmaceuticals as they bring their mental health treatment to market for patients who may benefit from this new therapeutic option.

A group of nearly 40 healthcare executives from around the world recently completed an intensive tour of Israel’s medical innovation centers, exploring how groundbreaking research transforms into life-saving technologies used globally.

The delegation arrived at the Weizmann Institute of Science in Rehovot on a clear February day, though visible damage from an earlier Iranian missile strike served as a stark reminder of ongoing regional tensions. The attack had destroyed dozens of laboratories conducting critical cancer and disease research.

Dr. Daniel Kraft, founder of Exponential Medicine and a physician-scientist working at the crossroads of technology and healthcare, shared his perspective with The Media Line. “The future of health and medicine is coming faster than you think,” Kraft said. “It’s not the technology; it’s often the convergence of a new operating system for the future of health and medicine.”

According to Kraft, Israel’s unique advantage lies in its concentrated environment where artificial intelligence, digital health tools, diagnostic systems, and clinical facilities operate within close proximity. This density speeds up the development process significantly. “Health and medicine are a universal need and collecting point,” he explained, noting that medical collaboration often continues even when political relationships face challenges.

The visiting healthcare leaders participated in a program jointly organized by Israel Tech Mission and 8400 The Health Network, Israel’s primary HealthTech ecosystem accelerator. The network serves as a bridge connecting the country’s medical innovation ecosystem with global health sector leaders.

As the primary organization supporting Israel’s HealthTech and Life Sciences sector, 8400 The Health Network played a crucial role in designing the program’s agenda and facilitating connections between international visitors and key Israeli stakeholders.

The initiative aimed to showcase both current obstacles and emerging opportunities within the ecosystem, while identifying areas of mutual strategic benefit and establishing pathways for long-term investment, collaboration, and partnerships. The organization continues supporting ongoing relationships, helping transform initial meetings into enduring partnerships and sustained strategic involvement.

The participants included investors, company founders, advisors, and operators from the United States and international markets, all sharing a common goal: understanding how laboratory discoveries in Israel successfully transition into global healthcare applications.

David Siegel, chairman and founder of Israel Tech Mission, helped structure the week-long program. He characterized the initiative as an opportunity to expose participants to both promising companies and the fundamental operating principles of Israel’s innovation ecosystem.

“We don’t bring people here just to see companies. We bring them here to understand how the system works,” Siegel explained to The Media Line. For him, this distinction is crucial, as the goal involves creating lasting relationships that continue developing well beyond the formal meetings.

David Nakar, the mission’s executive director, coordinated the week’s complex logistics and arranged meetings across research institutions, hospitals, and startup facilities. “Israel’s advantage isn’t just density of talent—it’s velocity,” Nakar told The Media Line. “But velocity needs channels. Delegations like this create structured pathways between founders, researchers, operators, and capital allocators. When those pathways are intentional, the distance between lab discovery and global patient impact shortens dramatically.”

Mission participant Al Kinel expressed his enthusiasm about the experience to The Media Line. “I feel so proud and happy about what is occurring here and what’s coming out,” Kinel said. “I’m excited to be able to help take those innovations and get them out to the world and help let people learn about them.”

Kinel operates a health technology consulting firm called Strategic Interests and leads the New York Israel Chamber of Commerce, which fosters commercial and research connections between Israel and the United States. His work focuses primarily on helping medical innovations move beyond early-stage promise into actual implementation within American healthcare systems. “There are people that are going to be supportive and helpful, and we will figure out how to work with them to help us be successful, and then there’s the undecided,” he said. “I want them to understand the value of the innovation of Israel and how it’s changing the world in tikkun olam [‘healing the world’].”

He acknowledged the challenging global environment surrounding these efforts. “Unfortunately, we’re in a spot in a world where there are people who are going to hate us and will never want to listen,” he said. “That’s not our audience.” His focus remains on those willing to consider evidence and engage in collaboration. From his perspective, exporting medical technology represents more than just economic activity—it becomes a form of engagement based on measurable results. “If we can align, we will probably be way more impactful than we each could in our own individual way,” he added.

While Kinel emphasized alignment, Sam Moed discussed organizational structure.

As a global board member of 8400 The Health Network, Israel’s national HealthTech ecosystem accelerator, Moed described the organization’s dual mission. “We are very focused on supporting and strengthening the health care system in Israel,” he told The Media Line, “but at the same time, we are building bridges globally.”

For Moed, these international connections serve practical purposes. Israel produces substantial early-stage medical innovation, but scaling these technologies requires access to global capital and markets. “The United States is the largest source of life sciences capital in the world,” he said. Without connecting to that ecosystem, promising technologies may fail to reach patients.

“I am very optimistic about the magnitude of disruptive innovation that is coming out of Israel,” Moed stated. The goal, he suggested, involves not just incremental improvements but establishing healthcare alongside cybersecurity and defense as one of Israel’s defining pillars. “We want health care to be one of those pillars.”

He noted that local challenges often generate globally applicable solutions. Referencing trauma care and mental health innovation, Moed observed that real-world experience has shaped technologies now attracting international attention. “Some of the innovation agenda is driven by the problems we face here,” he said. In this way, the country’s constraints have produced exportable expertise.

During the week, the delegation met with participants operating at every level of Israel’s health system, from capital formation to clinical application. The program included sessions with venture capital leaders and life sciences investors, hospital-based innovation teams integrating digital tools into patient care, early-stage founders developing diagnostics and therapeutic platforms, and professionals working in trauma and mental health in southern Israel following the October 7 events. Rather than focusing on individual companies, the schedule exposed participants to the structural elements of the ecosystem: academic research, clinical integration, capital formation, and resilience-driven innovation, and how these components interact.

At the Weizmann Institute of Science, conversations focused on translational pathways. Researchers explained their approach of designing studies backward from proof of concept and regulatory milestones, rather than forward from curiosity alone.

During one smaller breakout session, a group met with Professor Ravid Straussman, a physician-scientist in the Department of Molecular Cell Biology at the Weizmann Institute of Science. From his office, Straussman presented the progression of his research and how it has developed into three startups focused on cancer treatment. His work centers on identifying specific bacteria and fungi living within tumors, discoveries that are changing how certain cancers are understood and treated therapeutically. By analyzing the tumor microbiome, his team has opened new strategies for targeting cancer and potentially strengthening patients’ immune responses.

The discussion reflected a broader theme of the visit: the transition from discovery to practical application. Straussman described not only the scientific breakthrough, but the process of translating that breakthrough into structured ventures designed to carry the research beyond academic settings. For participants evaluating Israel’s health ecosystem, the session provided a concrete example of how basic science can develop into companies with international clinical significance.

Jonathan Sheffi, vice president of strategy and product excellence for the Life Sciences & Healthcare division at Clarivate, said the visit has already prompted him to pursue a structured initiative. Speaking with The Media Line, he stated, “I will create a business plan to develop a translational research platform based on Israel’s patient-level data.” The intention, he explained, involves not incremental collaboration but systematic leverage. “Through this platform, I hope to spur financial and human capital investment in Israel by large pharmaceutical companies,” he noted. By building on what he described as Israel’s strengths in “software, data science, and AI,” Sheffi added that he hopes to help “create a new generation of Israeli drug discovery companies.”

“It was announced that I will be joining the board of directors of Compugen,” Michele Holcomb told The Media Line, referring to the Israeli biotechnology company. Holcomb, a board director at PureTech Health and a veteran biotech and pharmaceutical executive, noted that the dialogue and interviews related to the appointment preceded the visit. Still, the timing highlighted the depth of integration between Israeli life sciences and global industry leadership. The flow of expertise, she suggested, moves in both directions.

Lee Shapiro’s relationship with Israeli health technology spans more than two decades. As co-founder of Chicago-based 7wire Ventures, he has observed the ecosystem evolve from early digital health experiments to mature global companies. “Israel had a very organized longitudinal record for every citizen in Israel, kind of cradle to grave health information that existed,” he said, recalling the early infrastructure that allowed companies to innovate around data long before it became common elsewhere.

Today, he sees few comparisons. “There really is very little comparison,” he said. “Israeli companies and their technology base are far advanced from where European companies have been and what we see coming out of Asia.” At the same time, he believes awareness lags behind reality. “We need more stories told about the life-saving technologies,” Shapiro said. “I don’t think people realize that some of the great medications that they’re using every day have come from Israel.”

Those medications, devices, and digital platforms are integrated into health systems across North America, Europe, and Asia. Their impact is measured in survival rates, early diagnoses, and more efficient care pathways. Shapiro framed that reach culturally. “The spirit of tikkun olam in terms of healing the world is something that is part of the ecosystem here and is something that’s used in a way that can not only create great markets but also do good for the rest of the world,” he said.

The conversation at Startup Nation Central expanded the perspective further. There, attention turned to infrastructure: mapping innovation, matching investors with startups, and supporting regulatory and market entry abroad.

Innovation, in Rob Cronin’s view, carries another dimension. As founder and CEO of 120/80 GROUP, a New York-based communications firm specializing in health technology, he sees economic impact and diplomacy intersect. “What I see as the opportunity and the ultimate form of diplomacy and the mechanism by which we can fight antisemitism is an economic, innovation-based form of tikkun olam,” he told The Media Line. “It’s about improving people’s lives.”

Michelle Garland, founder and CEO of Soul Search Partners, has spent more than two decades placing executive teams in venture-backed health technology companies. What impressed her most was not only product or capital, but people. “The talent here is exceptional, and the ideas are brilliant,” she told The Media Line. Sustained collaboration, she suggested, depends as much on relationships as financing. “We have to build more bridges,” she asserted.

By the end of the conversation, her reflection became personal. “I have a bigger tribe than I knew of,” she said, visibly moved. The remark pointed to something that ran beneath the week’s formal meetings: a sense that professional ambition, identity, and global health purpose were not entirely separate.

Participants repeatedly described an ecosystem that is compact yet internationally focused, technically rigorous yet commercially disciplined. Israeli medical innovation is developed with international application in mind. Therapies enter multinational trials. Digital platforms integrate into foreign health systems. Devices travel through supply chains that extend well beyond national borders.

For Moed, that orientation remains central. “We want Israel to be seen as a global health care innovation powerhouse,” he said. The measure is not visibility, but penetration into global health systems.

Israel’s growing role in global healthcare reflects more than scientific output. It reflects structure. As Kraft told The Media Line, “It’s often about connecting dots and getting people out of their old silos, their cognitive silos, their political silos, their belief silos, and better work together.” In a compact ecosystem where research, capital, and clinical infrastructure converge at close range, that ability to connect may be what places Israel at the center of how new medicine is built.

The final chapter of New York City’s historic nursing strike appears to be closing as the last group of striking healthcare workers has reached a preliminary contract agreement with their employer.

Officials from the New York State Nurses Association announced Friday that roughly 4,200 nurses at NewYork-Presbyterian hospital have secured a tentative deal that will go before union members for a vote over the weekend. The proposed contract includes wage increases exceeding 12% across a three-year period, maintains current health benefit protections, and establishes new guidelines governing artificial intelligence implementation in healthcare settings.

The labor dispute commenced on January 12 when 15,000 nursing professionals across three major hospital networks left their posts, demanding improved compensation and enhanced workplace safety measures. The widespread work stoppage created significant staffing challenges throughout the city’s healthcare system, prompting Governor Kathy Hochul to issue an emergency declaration that permitted medical workers from other states and countries to temporarily fill vacant positions.

Earlier this month on February 14, approximately two-thirds of the striking nurses resumed their duties following successful contract negotiations with Montefiore and Mount Sinai health systems.

Union President Nancy Hagans praised the NewYork-Presbyterian nurses’ determination in a statement announcing the breakthrough. “For a month-and-a-half, through some of the harshest weather this city has seen in years, nurses at NYP showed this city that they won’t make any compromises to patient care,” Hagans declared.

Hospital spokesperson Angela Karafazli expressed satisfaction with the resolution in her own statement. “We are pleased to have reached a tentative settlement with NYSNA, through the mediator, that reflects our tremendous respect for our nurses,” Karafazli commented.

Television star Eric Dane, beloved for his performances in “Grey’s Anatomy” and “Euphoria,” passed away this week at age 53 after battling amyotrophic lateral sclerosis, commonly known as ALS.

The progressive neurological condition took Dane’s life less than 12 months following his public announcement of the diagnosis, highlighting the aggressive nature of this devastating illness.

Data from the Centers for Disease Control and Prevention shows ALS affects a relatively small population. Researchers counted approximately 33,000 cases nationwide in 2022, with projections indicating the number could climb beyond 36,000 by the decade’s end.

The condition shows a slight preference for affecting males over females and typically emerges during middle age, most commonly striking individuals between 40 and 60 years old.

ALS targets nerve cells located in both the brain and spinal cord, resulting in progressive loss of muscle function that worsens as time passes.

The disease destroys nerve cells in both upper and lower regions of the body, causing them to malfunction and eventually die. When nerves can no longer activate specific muscles, patients gradually develop paralysis. Individuals diagnosed with ALS often experience difficulties with movement, speech, swallowing, and respiratory function.

Medical researchers have yet to identify the precise cause of this condition, though Mayo Clinic specialists note that a limited percentage of cases stem from genetic inheritance.

The alternate name “Lou Gehrig’s disease” honors the legendary New York Yankees baseball player who brought national attention to ALS. Gehrig received his diagnosis in 1939 on his 36th birthday, succumbed to the illness in 1941, and became the public face of ALS awareness for many years.

Medical professionals explain that initial symptoms often appear mild and easy to overlook. The condition frequently starts with muscle spasms and weakness affecting a single arm or leg.

As the disease advances, muscles lose their ability to function properly, according to specialists at University of California San Francisco Health. Patients may experience declining strength and coordination in their limbs, weakness in feet and ankles, and cramping or spasms in muscles of the arms, shoulders, and tongue. Difficulty swallowing and speaking often develop alongside persistent exhaustion.

UCSF medical experts emphasize that cognitive abilities and the five senses – sight, hearing, smell, taste, and touch – typically remain unaffected by the disease.

In advanced stages, muscles responsible for breathing may become paralyzed. Patients often lose the ability to swallow properly, leading to aspiration of food or saliva. Respiratory failure represents the leading cause of death among ALS patients.

Diagnosing ALS presents significant challenges since no single test or procedure can definitively confirm the condition. Medical professionals typically conduct comprehensive physical examinations, laboratory testing, and brain and spinal cord imaging.

Physicians look for specific indicators that may suggest ALS, including abnormal toe reflexes, decreased fine motor skills, painful muscle cramping, involuntary muscle twitching, and spasticity characterized by stiff, jerky movements.

While no cure exists for ALS, the medication riluzole has received approval for treatment purposes. Mayo Clinic research indicates this drug may prolong survival during early disease stages or delay the need for mechanical breathing assistance.

Relyvrio, another treatment option that generated significant controversy, was withdrawn from American markets by Amylyx Pharmaceuticals in 2024. The ALS Association, which gained prominence through the viral 2014 “ice bucket challenge” fundraising campaign, had partially funded the drug’s development.

Additional medications are sometimes prescribed to help manage specific symptoms as they arise.

As ALS progresses, choking becomes increasingly frequent, often necessitating feeding tube placement. Patients may require mobility aids like braces and wheelchairs, as well as communication devices including speech synthesizers and computer-based systems.

Following symptom onset, medical experts indicate survival times range from two years to a full decade. The majority of patients live between two and five years after symptoms first appear, while approximately 20 percent survive beyond the five-year mark following diagnosis.

JACKSON, Miss. — For the second consecutive day Friday, the University of Mississippi Medical Center kept its outpatient clinics shuttered and non-emergency surgeries postponed due to a cyber attack that infiltrated their computer networks.

Medical center administrators cautioned that the disruption may persist for several additional days while they assess the full scope of the cyber breach and work to bring back online the network infrastructure they deliberately shut down to prevent further damage.

Despite the clinic closures, hospital facilities and emergency departments continued normal operations, with patients receiving appropriate medical attention, according to Vice Chancellor LouAnn Woodward, who addressed reporters during Thursday’s press briefing. She explained that the cyber assault impacted numerous computer systems throughout the facility, including their digital patient records database.

“Some of us in the room have been here long enough that we remember taking care of patients with pen and paper,” she said.

Officials are currently investigating whether the attackers gained access to confidential patient data, Woodward indicated.

While confirming that the cyber criminals had made contact with university leadership, she declined to reveal what ransom demands were made. The medical center is coordinating response efforts with federal investigators.

During Thursday’s media briefing, FBI Special Agent in Charge Robert Eikhoff emphasized that the bureau’s primary focus centers on restoring the hospital’s technological capabilities to ensure uninterrupted patient treatment.

NEW YORK — A historic nursing walkout that has gripped New York City for more than a month appears ready to conclude after over 4,000 healthcare workers at NewYork-Presbyterian secured a preliminary contract agreement with hospital leadership in the early hours of Friday morning.

Union representatives and hospital administrators finalized the provisional accord, marking the end of negotiations at the final major medical center affected by the extended work stoppage, according to the New York State Nurses Association. Specific terms of the agreement were not made public.

The preliminary contract must now receive approval from union membership through a ratification vote. Should nurses approve the deal, they could resume their duties as soon as the coming week.

“We are pleased to have reached a tentative settlement with NYSNA, through the mediator, that reflects our tremendous respect for our nurses — the settlement is still subject to ratification,” stated Angela Karafazli, a spokesperson for NewYork-Presbyterian.

The approximately 4,200 healthcare workers at NewYork-Presbyterian represented the final group continuing their protest amid brutally cold winter conditions in what union officials characterized as the city’s most extensive and prolonged nursing work stoppage on record.

NYSNA president Nancy Hagans emphasized the significance of their persistence, saying, “For a month and a half, through some of the harshest weather this city has seen in years, nurses at NYP showed this city that they won’t make any compromises to patient care. The wins of our private sector nurses will improve care for patients, and their perseverance and endurance have shown people worldwide the power of NYSNA nurses.”

Earlier this month, approximately 10,500 healthcare workers at Mount Sinai and Montefiore medical facilities approved new three-year employment agreements on February 11th. Union officials reported that these contracts at Montefiore and Mount Sinai featured salary increases exceeding 12% across the three-year period.

The approved agreements also preserved existing healthcare benefits without additional employee expenses and established new workplace violence protections, with special focus on transgender and immigrant staff and patients. The contracts additionally created safeguards regarding artificial intelligence implementation in medical settings.

Healthcare workers at NewYork-Presbyterian declined to accept the terms offered in the February 11th agreements.

The work stoppage commenced on January 12th, affecting three of the city’s most prominent and respected private healthcare networks.

Medical facilities brought in numerous temporary nursing staff to address personnel shortages during an intense influenza season, creating anxiety among some of the hospital system’s most at-risk patients and their families.

Throughout the challenging and sometimes heated negotiations, hospital leadership argued that union demands were excessive and unrealistic. Healthcare workers responded that senior hospital executives earn millions annually while burdening nursing staff with overwhelming patient loads.

Earlier this month, an arbitrator granted nearly $400,000 in compensation to certain nurses at NewYork-Presbyterian’s Morgan Stanley Children’s Hospital for working under understaffed conditions during 2023 and 2024, union representatives announced, citing the ruling as validation of the issues that sparked the strike. NewYork-Presbyterian maintained that “safe staffing is always a priority” and noted the hiring of hundreds of nurses over the past three years.

The work stoppage did not impact all facilities within the NewYork-Presbyterian, Mount Sinai and Montefiore networks, and nursing staff at city-operated hospitals remained on duty. Additional private medical centers also secured last-minute agreements with union representatives.

Stock prices for cancer testing company Grail tumbled almost 50% during pre-market hours Friday following disappointing results from a comprehensive three-year clinical study that did not achieve its primary endpoint.

This disappointing outcome arrives shortly after Grail submitted an application to federal regulators seeking approval for its Galleri blood test, using information from both a smaller domestic study and initial data from the extensive three-year research project.

The comprehensive study aimed to demonstrate whether the blood test could decrease diagnoses of advanced-stage cancers while improving early detection rates within England’s National Health Service, potentially informing decisions about implementing a nationwide screening initiative.

Following Thursday’s market close, Grail announced that while the study did not achieve statistically significant reduction in late-stage cancer detection, “a favorable trend was observed over time” throughout the research involving more than 142,000 participants between ages 50 and 77 within the NHS system.

The biotechnology firm had filed its premarket approval request with the U.S. Food and Drug Administration in late January, utilizing results from approximately 25,000 American participants along with first-year findings from the NHS-Galleri study.

Currently, the Galleri multi-cancer detection test is already available for adults at higher cancer risk, particularly those 50 years and older.

Financial analyst Kyle Mikson from Canaccord Genuity noted that while FDA clearance for Galleri doesn’t seem to face significant risk, questions remain about whether the Centers for Medicare and Medicaid Services will factor in the NHS results when establishing coverage guidelines.

President Donald Trump recently enacted legislation this month that will allow Medicare insurance plans to cover multi-cancer detection tests for senior citizens beginning in 2028, with eligibility based on age requirements.

“We believe it is relatively likely that CMS will emphasize U.S.-based studies… rather than the specific endpoints that NHS established,” Mikson stated.

The Centers for Disease Control and Prevention has canceled a planned meeting of its vaccine advisory panel originally set for late February, according to a Department of Health and Human Services spokesperson.

The Advisory Committee on Immunization Practices, known as ACIP, was supposed to convene from February 25th through 27th. Officials have not announced when the meeting might be rescheduled.

This development occurs as Health Secretary Robert F. Kennedy Jr. continues his push to transform the nation’s vaccination policies. His initiatives include eliminating broad recommendations for six childhood vaccines such as COVID and hepatitis B shots, expanding federal support for state vaccine exemptions, and reducing funding for mRNA vaccine research.

The advisory panel plays a crucial role in determining vaccination recommendations, which typically influence health insurance coverage decisions, state school vaccination requirements, and how doctors counsel patients and families about immunizations.

The committee underwent significant changes last year when Kennedy dismissed all 17 of its members in June, leading to multiple restructuring efforts.

These changes coincide with a leadership transition at the CDC. Jay Bhattacharya, who currently serves as National Institutes of Health Director, will take over as acting CDC director, according to a Trump administration official who spoke Wednesday. He will replace the current acting director, Jim O’Neill.

MADISON, Wis. — Wisconsin legislators are moving forward Thursday with plans to approve extended Medicaid benefits for new mothers, a development that will isolate Arkansas as the nation’s lone holdout on postpartum healthcare coverage expansion.

For years, Wisconsin Democrats and many Republicans have advocated for lengthening Medicaid benefits for mothers after delivery, but faced consistent opposition from influential GOP Assembly Speaker Robin Vos. While Vos previously resisted what he viewed as welfare program growth, he changed course late Wednesday evening.

Thursday’s Assembly agenda includes voting on the maternal Medicaid extension alongside another bipartisan proposal mandating insurance coverage for enhanced breast cancer screenings for women with dense breast tissue.

The state Senate has already given overwhelming approval to both proposals, sending them to Democratic Governor Tony Evers, who is anticipated to sign the legislation next week.

Following Wisconsin’s expected action, Arkansas will stand alone without expanded postpartum Medicaid benefits.

Arkansas, which records among America’s highest rates of maternal deaths, did enact substantial maternal healthcare reforms last year. The state now provides temporary Medicaid access for pregnant women during eligibility review periods and covers doula care plus remote vital sign monitoring.

However, the Arkansas legislation stopped short of extending postpartum Medicaid duration, disappointing Democrats and some GOP members.

Republican Governor Sarah Huckabee Sanders advocated for the maternal health package while rejecting the postpartum extension, maintaining that alternative coverage exists.

In Wisconsin, approval of the Medicaid expansion and breast screening measures resolves a legislative standoff occurring during intense final negotiations of the two-year session. Republicans and Evers continue discussing potential agreements on tax reductions, education funding, and additional priorities, utilizing the state’s projected $2.5 billion budget surplus.

Democratic Assembly Minority Leader Greta Neubauer spearheaded efforts to advance both the Medicaid and breast screening legislation. Announcing her pregnancy Wednesday while revealing her mother’s breast cancer diagnosis, Neubauer declared Democrats would “stop at nothing to get a vote on these bills.” She described the anticipated passage as “an incredible win for women and the people of Wisconsin.”

Republican legislators, including Senate Majority Leader Devin LeMahieu, also shared personal accounts of breast cancer’s impact on family members while supporting the screening legislation.

The Medicaid expansion will enable low-income mothers earning above poverty thresholds to maintain state Medicaid enrollment for twelve months following delivery, replacing the current two-month limitation.

Despite consensus on these issues, numerous other prominent proposals appear destined to expire with the session’s end. Republicans haven’t reached agreement on funding to maintain WisconsinEye, the state’s nonprofit equivalent to C-SPAN.

Wisconsin’s nearly four-decade-old land conservation initiative also faces potential termination as lawmakers remain deadlocked on continued funding beyond June 30.

For years, Republicans have criticized the conservation program as overly costly and removing excessive acreage from property tax collections, damaging local governments. Proposals to preserve the program with significantly reduced funding have stalled.

Zimbabwe’s health officials launched distribution of a groundbreaking HIV prevention medication on Thursday, positioning the African nation among the first worldwide to implement this innovative treatment approach as it works to reduce new HIV cases.

The initiative, supported through funding from the United States and the Global Fund, will initially serve more than 46,000 individuals considered at elevated risk for HIV infection at 24 locations across the country, according to Health Minister Douglas Mombeshora.

“Today marks an important day in Zimbabwe’s national response to HIV. We gather here to launch lenacapavir — a long-acting injectable option for HIV prevention — and to show our commitment to protecting life and ending AIDS as a public health threat,” Mombeshora stated.

The minister revealed that Zimbabwe obtained its initial supply and provided injections to some early participants earlier in February, noting that distribution will proceed through multiple phases.

The medication lenacapavir, created by Gilead Sciences, requires administration through under-the-skin injections just twice annually. Health officials believe this approach may address compliance issues that occur with daily oral pre-exposure prophylaxis medication regimens.

The southern African country has achieved remarkable success in combating HIV, meeting the ambitious 95-95-95 treatment goals established by UNAIDS — indicating that 95% of HIV-positive individuals are aware of their condition, 95% of diagnosed patients receive treatment, and 95% of treated patients maintain undetectable virus levels.

Melody Dengu, a community advocate from Epworth, a Harare neighborhood, confirmed she received her injection earlier this month.

“I have also (so far) gotten 12 other people to come and get injected,” she shared with reporters during the announcement.

While Zimbabwe continues to face one of Africa’s most significant HIV challenges, new infection rates have dropped substantially during the last ten years through expanded testing, treatment access, and prevention efforts.

WASHINGTON — Federal health regulators are abandoning a decades-old practice that required pharmaceutical companies to conduct two comprehensive clinical trials before winning approval for new medications, marking another significant policy shift under the Trump administration’s push to accelerate medical product availability.

The Food and Drug Administration announced that moving forward, agency officials will typically demand just one clinical study for new medications and innovative health treatments, according to FDA Commissioner Dr. Marty Makary and deputy Dr. Vinay Prasad, who detailed the policy change in Wednesday’s New England Journal of Medicine.

This represents the most recent example of Makary and his leadership team overhauling established FDA protocols and standards, with officials citing goals to eliminate regulatory red tape and fast-track new treatment options for patients.

Following his appointment to the agency in April, Makary has implemented multiple policy changes designed to reduce FDA review timelines, including requiring staff members to utilize artificial intelligence tools and establishing expedited one-month review processes for drugs deemed important to “national interests.”

The new approach stands in stark contrast to the FDA’s stricter policies regarding other medical products, particularly vaccines.

In their Wednesday publication, Makary and Prasad argued that eliminating the dual-trial mandate reflects contemporary scientific progress that has made pharmaceutical research “increasingly precise and scientific.”

“In this setting, overreliance on two trials no longer makes sense,” the officials wrote. “In 2026 there are powerful alternative ways to feel assured that our products help people live longer or better than requiring manufacturers to test them yet again.”

FDA leadership anticipates the policy modification will trigger “a surge in drug development.”

Dr. Janet Woodcock, who previously directed the FDA’s drug division, endorsed the change as logical and consistent with the agency’s gradual shift over recent decades toward accepting single trials supported by additional evidence, particularly for life-threatening conditions like cancer.

“The scientific point is well taken that as we move toward greater understanding of biology and disease we don’t need to do two trials all the time,” stated Woodcock, who oversaw the FDA’s drug center for more than two decades before her 2024 retirement.

The dual-study requirement originated in the early 1960s when Congress enacted legislation mandating FDA review of data from “adequate and well-controlled investigations” before approving new treatments. For many years, agency officials interpreted this mandate as necessitating at least two comprehensive studies, typically involving large patient populations and extended monitoring periods.

The purpose behind requiring a second trial was to verify that initial study outcomes weren’t anomalous and could be replicated in different circumstances.

However, starting in the 1990s, FDA officials increasingly began accepting single studies for treatments targeting rare or deadly diseases, where companies frequently face challenges conducting large-scale patient trials.

During the past five years, approximately 60% of groundbreaking drugs approved annually have received clearance based on single studies. This trend reflects congressional legislation directing regulators toward greater flexibility when evaluating treatments for severe or difficult-to-treat medical conditions.

According to Woodcock, Wednesday’s policy announcement will primarily affect medications for common diseases that previously didn’t qualify for reduced testing requirements.

“It’s not the cancers and the rare diseases that will be affected by this,” she explained. “The agency has been approving those on a single trial already.”

The current FDA leadership’s strategy contrasts sharply with recent agency decisions regarding vaccines, gene therapies, and other treatments.

Last week, the FDA’s vaccine division, under Prasad’s direction, initially rejected Moderna’s application for a new mRNA influenza vaccine, citing inadequate clinical trial data. However, on Wednesday, the agency reversed its position and agreed to review the vaccine after Moderna committed to conducting additional studies involving elderly patients.

Additionally, Prasad has declined approval for numerous experimental gene therapies and biotechnology drugs, demanding additional research or more conclusive evidence. This pattern has negatively impacted biotech company stock values and contradicted Makary’s public statements promoting expedited and flexible FDA reviews.

Woodcock noted that pharmaceutical companies must wait to determine whether the FDA’s approach to promising experimental treatments will actually change.

“Implementation will be everything,” she said. “Since the agency’s approach is unclear, and the industry is already baffled, I don’t think this adds any illumination.”

WASHINGTON – Jay Bhattacharya, currently serving as director of the National Institutes of Health, has been tapped to simultaneously lead the Centers for Disease Control and Prevention on an interim basis, according to an administration source who spoke Wednesday.

The appointment was initially disclosed by The New York Times and later verified by the official, who requested anonymity since the decision had not yet been publicly announced.

This appointment makes Bhattacharya the third person to helm the troubled CDC, America’s premier public health organization, since President Donald Trump began his second presidency. Health Secretary Robert F. Kennedy Jr. suddenly dismissed former CDC Director Susan Monarez during the summer, barely four weeks after senators had approved her nomination.

Monarez, who had spent years working as a government researcher, subsequently appeared before a Senate panel where she revealed that Kennedy terminated her employment after she declined to approve his proposed modifications to children’s immunization schedules without supporting scientific evidence.

Jim O’Neill, the Deputy Health Secretary and former investment professional, had been filling the acting CDC director position and supervising the vaccine policy revisions until his reported exit the previous week.

As a health economics expert and former Stanford University faculty member, Bhattacharya gained attention for his vocal opposition to the federal government’s coronavirus lockdown measures and vaccination mandates. In his NIH role, he manages the country’s most significant source of biomedical research funding.

During a recent congressional hearing, Bhattacharya stated that childhood measles vaccination represented “the best way to address the measles epidemic in this country,” and confirmed he had found no proof connecting individual vaccines to autism.

Trump administration representatives have indicated their intention to identify a long-term CDC director, a position that must receive Senate approval.

The head of the National Institutes of Health will now also oversee the Centers for Disease Control and Prevention on an interim basis, according to a Wednesday report from The New York Times.

Jay Bhattacharya, who currently serves as NIH director, has been tapped to take on the acting director role at the CDC as well, two administration officials told the newspaper.

The dual appointment means Bhattacharya will simultaneously lead both major federal health agencies during this transitional period.

A West African nation has permanently terminated a controversial vaccine research project that received $1.6 million in funding during the Trump presidency, according to the country’s top diplomat.

Guinea-Bissau’s Foreign Minister Joao Bernardo Vieira announced Tuesday that his government has definitively ended the study, which was designed to examine potential side effects of hepatitis B vaccination, including exploring connections to autism.

“It’s not going to happen, period,” Vieira stated during an interview, explaining that the decision came after widespread criticism from both the scientific community and U.S. lawmakers.

The research proposal had generated significant controversy among medical experts and international health organizations. The World Health Organization’s Director-General Tedros Ghebreyesus declared the study unethical, particularly because the trial design meant only half of participating newborns would receive the hepatitis B vaccine immediately after birth.

Guinea-Bissau, among the most economically disadvantaged nations in West Africa, experiences elevated rates of hepatitis B infection. The country had initially paused the research last month while conducting an ethical evaluation.

Opposition to the study intensified because critics argued it was being used to validate theories connecting vaccines to autism – claims frequently promoted by current U.S. Health Secretary Robert F. Kennedy Jr., despite contradictory scientific evidence.

The Centers for Disease Control and Prevention had authorized the $1.6 million grant following Kennedy’s decision to eliminate the agency’s guidance recommending hepatitis B vaccination for all American newborns.

Medical data from Johns Hopkins University indicates that approximately 90% of infants exposed to hepatitis B during birth or their first year develop chronic infections, with 15% to 25% eventually dying prematurely from liver complications or cancer.

The study was being conducted by researchers from the Bandim Health Project, operated by the University of Southern Denmark and based in Guinea-Bissau. The research team planned to enroll 14,000 newborns to investigate what they termed “non-specific effects,” including skin conditions and neurodevelopmental issues such as autism.

Currently, Guinea-Bissau administers the hepatitis B vaccine at six weeks of age, by which time many babies born to infected mothers have already contracted the virus. The nation plans to begin birth-dose vaccination in 2028.

The proposed trial would have given half the participating infants the vaccine at birth, while the remaining half would receive it at the current six-week timeline.

Frederik Schaltz-Buchholzer, who was leading the investigation, expressed disappointment that the discussion had become politically charged rather than focusing on scientific merit.

“Everyone will lose if this trial is halted but, especially, confidence in vaccines and health research will suffer greatly,” Schaltz-Buchholzer commented, adding that his team remains hopeful a revised study proposal might gain approval in the future.

The Bandim project has maintained operations in Guinea-Bissau for multiple decades, with researchers stating their mission involves comprehensively understanding vaccines’ complete effects, both beneficial and harmful.

Kennedy has referenced Bandim research findings to support his decision to reduce U.S. funding for Gavi, an organization that facilitates vaccine purchases for the world’s most impoverished nations.

CDC representatives did not provide comments when contacted about the study’s termination.

A new study published Wednesday in a medical journal shows that approximately 3 million Americans enrolled in Medicare Advantage programs were compelled to seek new healthcare coverage, representing roughly 10% of all participants in these privately-operated plans.

The research, published in JAMA, revealed that residents in rural communities faced plan cancellations at twice the frequency of their urban counterparts. This disruption creates significant concerns about maintaining access to healthcare providers, specialized medical care, and ongoing treatments, according to Hannah James, a policy researcher with the RAND Corporation think tank, who authored an editorial alongside the study.

Seven states saw more than 40% of their Medicare Advantage participants affected by plan exits, with Vermont experiencing the most severe impact at 92% of enrollees. The remaining states included Idaho, Wyoming, North Dakota, South Dakota, Maryland, and New Hampshire.

Medicare serves approximately 60 million Americans who are either 65 or older or have qualifying disabilities. Roughly half choose Medicare Advantage plans operated by major insurance companies, while the remainder receive coverage through the traditional government-administered Medicare program.

During 2025, insurance companies reported financial losses after experiencing increased costs and reduced government payments, prompting announcements of market exits and shifts for 2026.

The study determined that enrollees with smaller insurance providers represented half of all those experiencing coverage disruptions.

UnitedHealthcare, owned by UnitedHealth Group, was responsible for nearly 14% of the disruptions. CVS Health’s Aetna division followed at 8.65%, while Elevance accounted for approximately 8% of the affected enrollees.

Research findings indicated that plans offering consumers broader provider networks were most commonly discontinued.

James explained in her editorial that the existing system, where the government compensates insurers through pre-arranged payments, creates incentives for companies to target more profitable patients.

“Policymakers should consider whether the current program design adequately aligns plan incentives with beneficiary needs,” James stated.

According to health policy organization KFF, UnitedHealthcare controlled nearly one-third of all Medicare Advantage plans in 2025. Humana held 17% of plans, followed by CVS Health at 12%, and Elevance at 7%.

Federal health officials have agreed to evaluate Moderna’s innovative influenza vaccine following an unprecedented public confrontation that initially prevented the company from submitting its application for the groundbreaking immunization.

The biotechnology company revealed this development on Wednesday, roughly one week after disclosing that federal vaccine regulators had declined to examine the new immunization, which utilizes Nobel Prize-recognized mRNA science.

The disagreement revolved around a large-scale clinical study involving 40,000 participants that demonstrated Moderna’s innovative vaccine outperformed existing standard flu immunizations in adults aged 50 and above. Federal vaccine oversight director Dr. Vinay Prasad issued an uncommon “refusal to file” notice, criticizing the research for excluding another vaccine brand specifically designed for individuals 65 and older.

Moderna challenged this decision publicly. The company argued that although federal regulators had suggested that particular testing approach, officials eventually approved the study’s framework. Additionally, Moderna provided supplementary comparison information from a different trial that utilized a high-dose immunization for senior citizens. Federal authorities identified no safety issues.

Nevertheless, Moderna announced Wednesday that as part of a settlement, the company will pursue complete authorization for vaccine use in adults between 50 and 64 years old, while seeking expedited approval for those 65 and above, contingent on conducting further research after market release. Company stock prices increased more than 5% following the morning announcement.

Federal regulators are aiming for a decision by August 5th, with Moderna expressing optimism about vaccine availability before year’s end. The company has also submitted approval requests in Europe, Canada, and Australia.

This remarkably public disagreement represents another indication of intensified federal vaccine oversight under Health Secretary Robert F. Kennedy Jr., especially regarding mRNA-based immunizations, which he has previously criticized both before and after assuming the nation’s highest health position.

Over the past year, federal health officials operating under Kennedy’s leadership have withdrawn COVID-19 vaccination recommendations, implemented additional warnings for the two primary COVID vaccines utilizing mRNA technology, and dismissed administration critics from federal advisory committees.

An Australian pharmaceutical company announced Wednesday it has secured exclusive rights to develop a potentially groundbreaking treatment for heart complications in patients with severe kidney disease.

CSL entered into a licensing deal with pharmaceutical giant Eli Lilly and Co, obtaining rights to develop and market clazakizumab, an antibody designed to reduce cardiovascular illness and death in patients with end-stage kidney disease.

Under the agreement, CSL will pay Eli Lilly $100 million upfront and could provide additional payments based on clinical trial results, regulatory approvals, and commercial success. The Australian company would also pay royalties on worldwide sales of the drug.

The treatment works by blocking a protein called IL-6 from connecting to its receptor, potentially reducing inflammation that contributes to disease progression in immune and inflammatory disorders, according to CSL.

“Clazakizumab is a promising therapeutic candidate with the potential to significantly impact the treatment landscape for various immuno-inflammatory and cardiovascular conditions,” said Bill Mezzanotte, head of research and development at CSL.

The Australian biotechnology company noted that finalizing the agreement depends on meeting standard closing requirements.

Aviv Shapira received a PTSD diagnosis in early 2023 following challenging military service that concluded before the October 7 attacks and subsequent conflict.

Watching their daughter struggle with inadequate support, her parents Avital and Moti Shapira recognized that numerous women dealing with military-related trauma weren’t receiving appropriate assistance.

This realization prompted them to take action and establish change.

The family created Arim Roshi (meaning “I shall rise”), a community support network for women with combat PTSD, originally scheduled to begin operations in 2024. However, following the October 7 massacre, the Shapiras moved up their timeline and launched the organization ahead of schedule, establishing a dedicated healing environment for women.

During Sunday’s ICAR (Israel’s Collective Action for Resilience) Summit presentation, Avital Shapira explained that her daughter rejected all available support programs. Initially puzzled by this response, she later understood that existing programs failed to address her daughter’s specific requirements.

“We realized women’s needs are very different from men’s,” Shapira said. “Just like physical health is different for men and women, so is mental health.”

Following decades of fighting for equal treatment in the Israel Defense Forces (IDF), women now serve in combat and police positions alongside their male colleagues. However, while receiving identical field treatment, military approaches to PTSD prevention and care frequently overlook gender-based differences.

Recent Ynet statistics reveal that women comprised approximately 20% of IDF combat personnel during the latest conflict, totaling over 65,000 female service members. These women participated in border protection, counterintelligence, and additional frontline operations. Similar to their male colleagues, many now face post-traumatic challenges.

Latest data from the Ministry of Defense rehabilitation department indicates that among more than 82,000 wounded personnel under their supervision, 31,000 are managing psychological wounds and post-trauma conditions.

Arim Roshi operates on four foundational elements: community support, therapeutic workshops, individual guidance, and research initiatives.

“Many women think they’re the only ones dealing with this,” Shapira explained. Arim Roshi creates a safe space where members can connect, share their experiences, and support one another.

The group conducts workshops incorporating movement, artistic expression, aquatic therapy, and horse-assisted treatment to help women work through trauma using methods beyond conventional talk therapy.

Additionally, Arim Roshi offers individual assistance to help women handle bureaucratic processes, manage family relationships, and complete Ministry of Defense recognition procedures.

The organization also monitors results and collects information about effective methods, aiming to support broader research efforts and enhance care for women with military-related PTSD.

Shapira joined other speakers addressing women and warfare issues during a panel led by Israel’s special envoy for trade and innovation, Fleur Hassan-Nahoum. The discussion examined distinctive wartime challenges facing women and institutional improvements needed to better serve them.

“The health of women is not just related to gynecology,” said Dr. Michal Sela of NOGAFem, a center for health innovation and policy. “We are different in every way.”

Despite this awareness, Sela noted that research and information about female fighters’ wartime experiences remains insufficient.

“The information is lacking,” Sela said.

The consequences reach well beyond frontline female personnel.

Dr. Inbal Shlomi from the Merhavim Medical Center for Brain and Mind Care described nationwide trauma levels as “unbelievable.”

“Even though most of us were not in Gaza or on the frontline, we all experienced unbelievable levels of trauma,” Shlomi explained. Social media exposure and constant interaction with people directly affected by the attacks contributed to widespread secondary trauma.

Furthermore, hundreds of Israeli women suffered sexual assault and abuse by Hamas terrorists on October 7 and during captivity. Shlomi explained that women with previous sexual abuse experiences might have experienced intensified symptoms, renewed flashbacks, or worsening PTSD after learning about their peers’ experiences that day.

She shared details about one patient who explained that before October 7, she considered the world evil but thought she might be wrong and attempted to challenge that viewpoint. Following October 7, she stated that nobody could persuade her otherwise.

Mothers also experienced profound trauma.

Agamit Gelb, who founded Inner Forces, described becoming a mother, sister, and aunt to fighters on October 7. While sending family members into combat, she realized she was experiencing complex emotions that seemed unrecognized by others.

Initially, few anticipated the conflict would continue for nearly two years, keeping loved ones on frontlines for extended durations. However, prolonged conflicts aren’t unprecedented for Israel. Gelb observed that her 70-year-old mother has served as a fighter’s mother, grandmother, and aunt throughout her life, yet remained overlooked in national discussions.

Gelb understood that mothers and other female relatives required support and clear information. However, the State failed to recognize their need for these resources.

She responded by establishing Inner Forces, a program designed for female family members of fighters. Working with Ruppin Academic Center, she researched 400 mothers. Results demonstrated that many women dismissed as simply anxious or concerned were actually experiencing trauma. About 20% of survey participants lost employment due to wartime challenges of being a soldier’s mother.

“The family is what provides resilience,” Gelb said, noting that keeping these women strong was essential.

Gelb reported that when asking mothers about their coping strategies, many would start crying. However, they frequently felt guilty about expressing distress because their sons hadn’t been killed or kidnapped.

“I was just a mom of someone in the field,” Gelb said, describing how she felt lost because she viewed her own trauma as less significant than others’.

Through Inner Forces, she established a community providing resilience programming, psychoeducation, and crucially, a gathering place for mothers to connect and support each other throughout the war.

As increasing numbers of women assume combat responsibilities and serve in critical IDF positions, understanding mental health protection becomes increasingly vital, Shapira emphasized. She noted that many women work in frontline positions not officially designated as combat roles, yet potentially expose them to equivalent trauma levels.

Nevertheless, she expressed optimism.

Her own daughter, who had suffered significantly, recently delivered her second child. She observed that many women who experienced early war trauma are now contributing to what she called a “baby boom.”

“There is hope,” she told the room. “You can live with PTSD,” she added, “and it can even be transformed into post-traumatic growth. That is our hope.”

Health authorities in South Carolina documented 12 new measles infections between Friday and Tuesday, pushing the state’s total confirmed cases to 962, according to data released by state health officials.

The Tuesday announcement marks a continued climb in what has become a significant outbreak, with health department leaders cautioning that the spread of the highly contagious disease may continue for weeks or even months to come.

Officials point to insufficient vaccination rates as a key factor allowing the outbreak to persist and expand throughout the state. The measles virus spreads rapidly in communities where immunization coverage falls below protective levels.

A pharmaceutical company announced Tuesday it will move forward with standard federal approval procedures for its rare disease medication after the Food and Drug Administration turned down its application for expedited review.

Disc Medicine revealed that federal regulators declined to approve bitopertin through the agency’s accelerated review system. Last month, Reuters reported exclusively that FDA officials had delayed the drug’s evaluation by two weeks due to questions about clinical trial information and concerns regarding potential misuse.

The medication had been under consideration through the FDA’s national priority voucher system, which reduces review time to one or two months compared to the standard 10-12 month timeline.

Company CEO John Quisel noted that policy discussions surrounding accelerated drug approvals have continued through several presidential administrations, with recent regulatory actions indicating federal officials are taking a more cautious approach to such expedited approvals.

The pharmaceutical firm indicated it anticipates receiving final-stage trial results during the fourth quarter of this year.

A Massachusetts pharmaceutical company announced Tuesday that its investigational treatment for a serious eye condition outperformed an existing approved medication in advanced clinical testing.

Ocular Therapeutix revealed that their experimental drug demonstrated superior effectiveness compared to Regeneron’s established treatment Eylea in helping patients preserve their eyesight during late-stage trials.

According to the company, this marks the first instance where an investigational medication for wet age-related macular degeneration has delivered better outcomes than an FDA-approved therapy in trials conducted under rigorous regulatory standards.

This progressive eye condition represents a primary factor in vision loss among older adults, resulting in fuzzy sight or dark spots within a person’s field of vision. The disease impacts approximately 1.7 million people across the United States, the company reported.

The clinical study included 344 participants recently diagnosed with wet AMD and showed that Ocular’s medication, called Axpaxli, delivered better results than Eylea, which ranks among the most commonly prescribed therapies for this condition.

Results showed that roughly 74% of participants receiving one 0.45 mg injection of Axpaxli retained their vision after 36 weeks, while approximately 56% of those given a single 2 mg injection of Eylea achieved the same outcome. At the one-year mark, close to 66% of Axpaxli recipients maintained their vision, compared to less than half in the comparison group.

Despite gaining nearly 39% in value during 2025, Ocular’s stock price dropped approximately 25% during pre-market trading following the announcement.

Needham analyst Serge Belanger noted that eye specialists may find the data encouraging, though investors might feel let down by “the much narrower difference” between the treatments and increased rates of eye floaters and cataracts.

The experimental medication also showed improved management of eye fluid accumulation, which serves as an important indicator of disease control.

The company reported that numerous Axpaxli patients avoided needing additional “rescue” treatments for nearly twelve months, indicating the therapy could potentially decrease required medical appointments.

Ocular Therapeutix stated they intend to review the trial data with federal regulators and anticipate filing for marketing approval based on these findings.

An Indian pharmaceutical company is working to bring a significantly more affordable version of a popular weight loss medication to market, potentially offering substantial savings for patients.

Dr Reddy’s Laboratories revealed Tuesday that it intends to offer a generic alternative to Novo Nordisk’s widely-used weight loss treatment Wegovy, with pricing approximately 60% below the brand-name version, according to co-chairman and managing director GV Prasad speaking with Reuters.

The pharmaceutical manufacturer secured authorization from India’s drug regulatory authority last month to produce and distribute a generic equivalent of the diabetes medication Ozempic, another blockbuster drug from Novo Nordisk. The company indicated it is currently waiting for similar regulatory clearance for its proposed Wegovy alternative.

The development comes as demand for these types of medications continues to grow, with many patients seeking more affordable options for weight management and diabetes treatment.

Compass Pathways announced Tuesday that its experimental depression treatment successfully achieved its primary objectives in a comprehensive late-stage clinical trial, causing the company’s stock price to surge nearly 30 percent.

The pharmaceutical company tested its therapy, known as COMP360, across two extensive clinical trials that included over 1,000 participants suffering from treatment-resistant depression.

The innovative treatment utilizes psilocybin, a psychedelic substance, and represents a potential breakthrough as a short-duration, periodic treatment option that could replace daily antidepressant medications.

According to the company’s findings from the most recent trial, participants who received two higher-strength doses administered three weeks apart demonstrated significantly greater improvement in their depression symptoms over a six-week period compared to those who received smaller doses.

Nearly 40 American healthcare executives recently completed a groundbreaking tour of Israeli medical research facilities, exploring how breakthrough discoveries are transforming from laboratory concepts into worldwide healthcare solutions.

The delegation arrived at the Weizmann Institute of Science in Rehovot during February, where they witnessed firsthand the resilience of Israeli innovation. Despite visible damage from an Iranian missile attack that destroyed numerous laboratories months earlier, researchers continued their vital work developing next-generation medical technologies.

The week-long visit was coordinated by Israel Tech Mission working alongside 8400 The Health Network, bringing together investors, company founders, advisors and healthcare operators from across the United States and international markets.

“I feel so proud and happy about what is occurring here and what’s coming out,” Al Kinel shared with The Media Line. “I’m excited to be able to help take those innovations and get them out to the world and help let people learn about them.”

Kinel, who operates a health technology consulting company called Strategic Interests and heads the New York Israel Chamber of Commerce, focuses his efforts on bridging Israeli medical breakthroughs with American healthcare systems. His work involves promoting commercial and research partnerships between the two nations.

“There are people that are going to be supportive and helpful and we will figure out how to work with them to help us be successful, and then there’s the undecided,” Kinel explained. “I want them to understand the value of the innovation of Israel and how it’s changing the world in Tikkun Olam.”

Acknowledging current global tensions, Kinel remained focused on productive collaboration. “Unfortunately, we’re in a spot in a world where there’s people that are going to hate us and will never want to listen,” he noted. “That’s not our audience.” His strategy centers on engaging those willing to consider evidence-based partnerships. “If we can align, we will probably be even way more impactful than we each could in our own individual way,” he added.

Sam Moed, serving on the global board of 8400 The Health Network, outlined the organization’s dual mission approach.

“We are very focused on supporting and strengthening the healthcare system in Israel,” Moed explained to The Media Line, “but at the same time, we are building bridges globally.”

These international connections serve practical purposes, according to Moed. While Israel produces substantial early-stage medical innovations, successful scaling demands access to worldwide capital and markets. “The United States is the largest source of life sciences capital in the world,” he emphasized. Without connecting to that financial ecosystem, promising technologies risk stalling before reaching patients who need them.

Moed expressed optimism about current developments. “I am very optimistic about the magnitude of disruptive innovation that is coming out of Israel,” he stated. His vision involves establishing healthcare as a cornerstone industry alongside Israel’s established cyber and defense sectors. “We want healthcare to be one of those pillars.”

Local challenges often generate globally applicable solutions, Moed observed. Referencing trauma care and mental health innovations, he noted how direct experience has shaped technologies now gaining international attention. “Some of the innovation agenda is driven by the problems we face here,” he said. This approach has transformed national constraints into exportable expertise.

Throughout the week, participants visited research institutions, nonprofit innovation centers and private companies. Discussions emphasized practical implementation: transforming discoveries into products, navigating regulatory requirements, and scaling companies effectively.

At the Weizmann Institute, conversations focused on translational pathways. Researchers described designing studies starting from proof of concept and regulatory milestones rather than beginning with curiosity alone. These discussions prioritized practical execution and commercialization strategies.

Lee Shapiro, co-founder of Chicago-based 7wire Ventures, has observed Israeli health technology evolution for over twenty years. He recalled early advantages that positioned Israeli companies ahead of global competitors.

“Israel had a very organized longitudinal record for every citizen in Israel, kind of cradle to grave health information that existed,” Shapiro remembered. This infrastructure enabled data-driven innovation long before it became standard elsewhere.

Today, Shapiro sees Israeli companies maintaining their competitive edge. “There really is very little comparison,” he stated. “Israeli companies and their technology base are far advanced from where European companies have been and what we see coming out of Asia.” However, he believes public awareness hasn’t kept pace with reality. “We need more stories told about the life-saving technologies,” he said. “I don’t think people realize that some of the great medications that they’re using every day have come from Israel.”

These medications, devices and digital platforms now operate within health systems throughout North America, Europe and Asia. Their effectiveness shows in improved survival rates, earlier diagnoses and more efficient care delivery. Shapiro connected this impact to cultural values. “The spirit of Tikkun Olam in terms of healing the world is something that is part of the ecosystem here and is something that’s used in a way that can not only create great markets but also do good for the rest of the world,” he explained.

Discussions at Startup Nation Central expanded the scope to infrastructure development: mapping innovations, connecting investors with startups, and supporting regulatory approval and market entry internationally.

Dr. Daniel Kraft, founder of Exponential Medicine and a physician-scientist working where technology meets healthcare, emphasized the accelerating pace of change.

“The future of health and medicine is coming faster than you think,” Kraft told The Media Line. “It’s not the technology, it’s often the convergence of a new operating system for the future of health and medicine.”

Kraft argued that ecosystems like Israel’s benefit from density – the close proximity of artificial intelligence, digital health, diagnostics and clinical systems within a concentrated area. This closeness speeds up development cycles. “Health and medicine is a universal need and collecting point,” he suggested, noting that healthcare collaboration often advances even during strained political relationships.

Rob Cronin, founder of a New York-based communications firm specializing in health technology, sees innovation carrying diplomatic implications.

“What I see as the opportunity and the ultimate form of diplomacy and the mechanism by which we can fight anti-Semitism is an economic, innovation-based form of tikkun olam,” Cronin told The Media Line. “It’s about improving people’s lives.”

Michelle Garland, founder and CEO of Soul Search Partners, has spent over twenty years placing executive teams in venture-backed health technology companies. Beyond products and capital, she was impressed by human resources.

“The talent here is exceptional and the ideas are brilliant,” Garland told The Media Line. She emphasized that lasting collaboration depends equally on relationships and financing. “We have to build more bridges.”

By week’s end, her reflection became personal. “I have a bigger tribe than I knew of,” she said, clearly moved. Her comment highlighted an underlying theme throughout the formal meetings: the connection between professional goals, personal identity and global health mission.

Participants consistently described an ecosystem that remains compact yet internationally focused, technically rigorous yet commercially practical. Israeli medical innovation develops with global implementation as the target. Treatments enter international clinical trials. Digital platforms integrate into foreign health systems. Medical devices move through supply chains extending far beyond national boundaries.

For Moed, this international orientation remains essential. “We want Israel to be seen as a global healthcare innovation powerhouse,” he stated. Success measures not by visibility alone, but by integration into worldwide health systems.

The week’s overall impression centered less on individual companies and more on systematic architecture. A nation with fewer than ten million residents has built a concentrated network of research institutions, capital access and translational expertise that consistently supplies global markets. In practice, this structure gives concrete form to Tikkun Olam – not as abstract concept, but through deployed therapies, adopted systems and treated patients extending well beyond Israel’s borders.

Source: https://srnnews.com/the-media-line-the-future-of-health-and-medicine-is-coming-faster-than-you-think-from-israeli-labs-to-global-health-systems/